

Subject Index—Volume 88

No. 1, January 1, pp. 1-244
 No. 2, January 15, pp. 245-490
 No. 3, February 1, pp. 491-710
 No. 4, February 15, pp. 711-968
 No. 5, March 1, pp. 969-1186
 No. 5, March 1, Supplement, pp. 1187-1276
 No. 6, March 15, pp. 1277-1508

No. 7, April 1, pp. 1509-1762
 No. 8, April 15, pp. 1763-1978
 No. 9, May 1, pp. 1979-2198
 No. 10, May 15, pp. 2199-2428
 No. 11, June 1, pp. 2429-2652
 No. 12, June 15, pp. 2653-2890
 No. 12, June 15, Supplement, pp. 2891-3108

A

Abdominal fibrosis, after intraperitoneal floxuridine, 2447
Accelerated Publication, 1
 Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
 Acute leukemia. *See* Leukemia, acute
 Adenocarcinoma. *See also specific sites and types of lung*, in young patients, 1837
 Adenomatous polyposis coli I1307K mutation, in Jews, 755
 Adolescents, T-cell-rich large B-cell lymphoma in, 2378
 Adrenocortical cancer
 cisplatin, etoposide and mitotane for, 1159
 clinicopathology of, 711
 Aerodigestive cancer. *See* Head and neck cancer
 Aflatoxin B1, p53 mutations in hepatocellular carcinoma and, 1565
 African Americans
 breast cancer survival in, 114
 pain management for, 1929
 Aggressive fibromatosis, surgery vs. radiotherapy for, 1517
 AIDS. *See* Human immunodeficiency virus infection
 Alaska Natives, breast cancer in, migration patterns and, 1203
 Alcohol use/abuse
 anti-CD4 antibody and, in nonsmall cell lung cancer, 468
 breast cancer and, 1239
 Alendronate, oral, for bone metastases, 6
 Allelic loss. *See* Loss of heterozygosity
 Allogeneic mixed lymphocyte culture, for pancreatic cancer, 1325
 Alpha-1-antitrypsin deficiency type PiZ, hepatic cancer and, 2669
 Alpha-fetoprotein
 vs. des-gamma-carboxy prothrombin, in hepatocellular carcinoma diagnosis, 544
 at recurrence of germ cell tumors, 162
 reduced, in hepatocellular carcinoma, 1557

Alternative therapies, with radiation therapy, for prostate cancer, 615
 American Cancer Society, national report on cancer of, 2398
 American Indians. *See* Native Americans
 American Joint Committee on Cancer Prognostic Factors Consensus Conference, for colorectal cancer, 1739
 American Joint Committee on Cancer Staging, revised staging system of, for melanoma, 1484
 5-Aminolevulinic acid-induced porphyrin fluorescence, in photodetection of cervical intraepithelial neoplasia, 2275
 Anal cancer, human papillomavirus-associated, in Hawaii, 1464
 Analgesia, for minority patients, 1929
 Androgen deprivation therapy, for prostate cancer, prostate specific membrane antigen expression after, 407
 Android obesity, breast cancer survival and, 2752
 Angiogenesis
 in brain tumors, hypoxia-inducible factor 1 α and, 2606
 in colorectal cancer
 p53 and vascular endothelial growth factor and, 1820
 tegafur suppositories and, 1007
 in gastric cancer, thymidine phosphorylase in, 2220
 in lung cancer, mast cell density and, 2687
 in metastatic nasopharyngeal cancer, vascular endothelial growth factor and, 255
 in pancreatic cancer, vascular endothelial growth factor and, 2239
 tissue factor and, in colorectal cancer, 295
 in transitional cell bladder cancer, thymidine phosphorylase and, 1131
 Anthracyclines, onycholysis and, 2367
 Antibiotic prophylaxis, oral, for febrile neutropenia, 2849
 Anti-CagA antibody, in risk assessment, for *H. pylori*-related gastric cancer, 1530
 Anti-CD4 antibody, in nonsmall cell lung cancer, alcohol use and, 468

Antigen(s)

- carbohydrate, in pancreatic cancer, as immunotherapy targets, 1828
- carcinoembryonic, in colorectal cancer, prognostic significance of, time-dependency of, 35
- proliferating cell nuclear
 - in gastric MALT lymphoma, 2210
 - in oligodendrogliomas, prognosis and, 862
- prostate specific
 - outcome after radiation therapy and, 2305
 - in radiation-treated prostate cancer, 2110
 - UICC workshop on, 955
- prostate specific membrane
 - after androgen deprivation surgery, 407
 - UICC workshop on, 955
- Thomsen-Friedenreich, in colorectal cancer, prognosis and, 1536
- Antiretroviral therapy, HIV-related non-Hodgkin's lymphoma outcome and, 1696
- Aortic dissection, extraperitoneal endoscopic, in cervical cancer, 1883
- Apoptosis
 - in atypical bronchopulmonary carcinoids, 1590
 - in colorectal cancer, tegafur suppositories and, 1007
 - paclitaxel-induced, mechanisms of, 2619
 - thiol-mediated, in prostate cancer, 2092
- Ara-C. *See* Cytarabine
- Arginine, with fish oil, for canine lymphoma, 1917
- Arm, lymphedema of, compression methods for, 2833
- Arthritis, quality of life and, 1175
- Artificial intelligence, in prediction of nodal metastasis, in prostate cancer, 2105
- Artificial neural networks, for prostate cancer
 - in risk assessment, 2655
 - UICC workshop on, 955
- Asian and Pacific Islanders, human papillomavirus-associated cancer in, 1464
- L-Asparaginase
 - for acute lymphoblastic leukemia, in second remission, 1166
 - for large cell lymphoma, in children, 166
- Assisted reproduction, pediatric cancer risk and, 2846
- Assisted suicide, Schedule of Attitudes toward Hastened Death for, 2869
- Astrocytoma
 - epidemiology of, in Sweden, 1492 (letter)
 - intraarterial chemotherapy and radiotherapy for, 2350
 - supratentorial, WHO classification of, 1477
- Ataxia telangiectasia, acute lymphoblastic leukemia and, ATM gene deletion and, 1057
- ATM gene deletion, in acute lymphoblastic leukemia, in adults, 1057
- Atypical nephrogenic metaplasia, 853
- Axillary node dissection
 - in breast cancer, 1852
 - vs. sentinel node biopsy, for breast cancer, morbidity after, 608
- Axillary radiotherapy, primary, for breast cancer, 1633

B

- Bandaging, for limb lymphedema, 2833
- Barrett esophagus adenocarcinoma, intestinal metaplasia as precursor of, 2520
- Basal cell carcinoma, Mohs micrographic surgery for, perineural spread after, 1605
- Basosquamous carcinoma, prognostic factors in, 1365
- Bax, in cervical cancer, after radiotherapy with/without thermotherapy, 132
- B-cell lymphoma, T-cell-rich, in children and adolescents, 2378
- Bcl-2
 - in cervical cancer, after radiotherapy with/without thermotherapy, 132
 - in gastric MALT lymphoma, 2210
 - in oligodendrogliomas, prognosis and, 862
- BCNU, for large cell lymphoma, in children, 166
- Biologic response modifiers. *See also specific modifiers*
 - with chemotherapy, for neuroblastoma, 2839
 - for metastatic melanoma, 1703
 - for pancreatic cancer, 1325
 - for renal cell carcinoma, 1892
 - with floxuridine, 1310
- Biopsy
 - lymph node, in breast cancer, with lymphoscintigraphy, 2546
 - sentinel node
 - accuracy of, in large breast tumors, 2540
 - vs. axillary node dissection, for breast cancer, morbidity after, 608
 - in breast cancer
 - accuracy of in large tumors, 2540
 - with lymphoscintigraphy, 2546
 - morbidity after, vs. with axillary node dissection, 608
 - pathologic findings in, 971 (editorial), 1099
- Bisphosphonates, oral, for bone metastases, 6
- Bladder
 - flat intraepithelial lesions of, cancer risk and, 625
 - paraganglioma of, 844
- Bladder cancer
 - flat intraepithelial lesions and, 625
 - human mismatch repair gene hMSH2 in, 2333
 - inverted urothelial papilloma and, 632
 - pathologic classification and grading system for, 1509, 1513
 - radical cystectomy for, outcome predictors for, 2327
 - transitional cell
 - ifosfamide, paclitaxel and cisplatin for, 1671
 - MIB-1 in, prognosis and, 2598
 - thymidine phosphorylase in, prognosis and, 1131
 - urothelial, grading of, 1663
- Bladder tumors, pathologic classification and grading system for, 1509, 1513
- Bleomycin, for Hodgkin's disease, 2142
- granulocyte-macrophage-colony stimulating factor pretreatment and, 454
- Body composition, as chemotherapy toxicity predictor, 796

- Body mass, breast cancer and, 1248
- Body weight, breast cancer and, 1248
- Bombesin antagonists, for breast cancer, 1384
- Bone, giant cell tumors of, in hand and foot, 2022
- Bone marrow metastasis, in breast cancer, in first recurrence, 2252
- Bone marrow necrosis, 1769
- Bone marrow recovery, in myelosuppressive therapy, FLT3-L as predictor of, 333
- Bone marrow staging, flow cytometric, in non-Hodgkin's lymphoma, 894
- Bone marrow transplantation, for breast cancer, with isolated supraclavicular nodal metastases, 790
- Bone metastasis
- oral bisphosphonates for, 6
 - pamidronate for, in breast cancer, 1082
 - primary site determination for, 1759 (letter)
- Bone sarcoma
- of flat bones, 324
 - granulocyte-macrophage-colony stimulating factor for, morning vs. night administration of, 2033
 - of head and neck, in children, 2172
- Brachytherapy. *See also* Radiation therapy
- for esophageal cancer, with chemotherapy, 988
 - for glioblastoma multiforme, 2797
- Brain, glucose metabolism in, after acute lymphoblastic leukemia, 693
- Brain tumors
- astrocytoma
 - epidemiology of, in Sweden, 1492 (letter)
 - intraarterial chemotherapy and radiotherapy for, 2350
 - supratentorial, WHO classification of, 1477
 - central neurocytoma, recurrent, chemotherapy for, 169
 - ependymoma, recurrent, stereotactic radiosurgery for, 870
 - glioblastoma, supratentorial, WHO classification of, 1477
 - glioblastoma multiforme
 - brachytherapy for, 2797
 - hypoxia-inducible factor 1 α in, 2606
 - glioma
 - diagnostic discrepancies in, 2342
 - hypoxia-inducible factor 1 α in, 2606
 - radiotherapy for, high-dose busulfan and thiotepa after, 685
 - hypoxia-inducible factor 1 α in, 2606
 - intraarterial chemotherapy for, with osmotic opening of blood-brain barrier, 637
 - in Li-Fraumeni syndrome, 433
 - long-term survivors of, cardiovascular disease in, 2116
 - meningioma, chromosome instability in, 440
 - oligodendroglioma, grade 2, prognostic factors in, 862
 - radiotherapy for, high-dose busulfan and thiotepa after, 685
 - supratentorial astrocytic, WHO classification of, 1477
 - supratentorial primitive neuroectodermal, treatment of, 2189
- BRCA1/2* mutations, breast cancer and, in young patients, 1393
- Breast cancer
- advanced, high dose epirubicin for, 375
 - alcohol and, 1239
 - android obesity and, survival and, 2752
 - axillary node dissection in, efficacy of, 1852
 - axillary tumor free lymph nodes in, number of, prognosis and, 108
 - bilateral, synchronous vs. metachronous, 2740
 - bombesin/gastrin-releasing peptide antagonists for, 1384
 - bone marrow micrometastasis in, with first recurrence, 2252
 - bone metastasis in, oral Bisphosphonates for, 6
 - BRCA1/2* mutations in, in young patients, 1393
 - breast-conserving therapy for, with coexistent lobular carcinoma, 978, 982 (editorials), 1072
 - current health practices and willingness to make lifestyle change in, 674
 - diet and, 1239, 1245
 - ductal, hormone replacement therapy and, 2570
 - ductal in situ
 - age-based pathologic differences in, 2553
 - local recurrence of, 1643
 - mammographically detected, local recurrence of after breast-conserving therapy, 596
 - pathology of, National Surgical Adjuvant Breast Project findings on, 1976 (letter)
 - treatment of, Consensus Conference on, 946
 - ductal in situ-flat type, genetic abnormalities in, 2072
 - 8p22 loss of heterogeneity in, prognosis and, 1410
 - environmental factors in, 1224
 - ethno-oncology and, 1189
 - etiology of, multicultural aspects of, 1187
 - exercise and, 1248
 - Fhit in, disease progression and, 1378
 - hormonal factors in, 1230
 - hormone receptors in, race and, 114
 - ipsilateral recurrence of, p53 mutation and, 1091
 - with isolated supraclavicular nodal metastases, chemotherapy and bone marrow transplant for, 790
 - lobular
 - hormone replacement therapy and, 2570
 - incidence of in older women, 2561
 - Mad1 protein expression in, 1623
 - in medically underserved, 1217
 - metastatic, survival in, 95
 - microinvasive, clinicopathology of, 1403
 - migration patterns and, 1203
 - minimally invasive surgery for, after chemotherapy downstaging, 1417
 - in Native Americans
 - migration patterns in, 1203
 - in urban environments, 1207
 - natural history of, screening and, 1758 (letter)
 - negative purging of peripheral blood stem cells in, 2754

node-negative, p53 and *c-erb* B-2 in, prognostic value of, 804
obesity and, 1248
paclitaxel and cisplatin for, 1863
physician's experience of, 2199
population-based research in, community involvement in, 1214
primary axillary radiotherapy for, 1633
radiation therapy for, quality of life and, 2260
raloxifene for, 2047
reproductive factors in, 1230
screening for
disease outcome and, 1758 (letter)
intervals for, 1282
sentinel node biopsy in
accuracy of in large tumors, 2540
with lymphoscintigraphy, 2546
morbidity after, vs. with axillary node dissection, 608
pathologic findings in, 971 (editorial), 1099
socioeconomic factors in, 1256
stage at diagnosis of, ethnicity and, 1193
survival in, racial differences in, 114
synucleins expression in, 2154
treatment and outcome in, age-related variation in, 369
treatment of, in low-income patients, 933
tumor biology in, ethnicity and, 1193
vinorelbine with paclitaxel for, 96-hour infusion of, 2732
Breslow thickness, in melanoma staging, 491 (editorial), 589
Bronchopulmonary carcinoids, atypical, apoptosis in, 1590
Busulfan, for gliomas, after radiotherapy, 685

C

CA 125, in advanced acute leukemia with serosal involvement, 75
Calcitonin, normalization of in medullary thyroid cancer, prediction of, 1909
Cancer
comorbidity in, epidemiologic and therapeutic aspects of, 663
national report on, 2398
terminal, Schedule of Attitudes toward Hastened Death for, 2869
Cancer care
palliative
needs assessment for, 900
pain diary in, 2387
Schedule of Attitudes toward Hastened Death in, 2869
quality assessment for, indicators for, 701
Cancer Genome Anatomy Project, 2
Cancer pain, undertreatment of, in minorities, 1929
Cancer patients
needs assessment for, 217, 900
physician as, 2199
Cancer survivors

cardiovascular disease in, 2116
current health practices and willingness to make lifestyle change of, 674
Caspase-3-mediated apoptosis, in prostate cancer, 2092
Carbohydrate antigens, in pancreatic cancer, as immunotherapy targets, 1828
Carboplatin
for breast cancer, with isolated supraclavicular nodal metastases, 790
for metastatic breast cancer, 124
Carcinoembryonic antigen, in colorectal cancer, prognostic significance of, time-dependency of, 35
Carcinoids, bronchopulmonary
apoptosis in, 1590
p16^{INK4A} and retinoblastoma proteins in, 550
Carcinoid syndrome, lanreotide vs. octreotide for, 770
Carcinosarcoma, uterine, surgical staging of, 2783
Cardiotoxicity, of paclitaxel, 2149
Cardiovascular disease, in long-term survivors of brain tumors, 2116
Carmustine, for large cell lymphoma, in children, 166
Carney syndrome, 964 (letter)
Carotenoids, gastric cancer and, 737
CD34, in acute myeloid leukemia, prognosis and, 2529
CDK4, in prostate cancer, prognosis and, 416
cDNA libraries, 2
Cefixime, prophylactic oral, for febrile neutropenia, 2849
Centers for Disease Control and Prevention, national report on cancer of, 2398
Central nervous system prophylaxis, for acute lymphoblastic leukemia, with extended triple intrathecal therapy and modified BFM chemotherapy, 205
Central nervous system thrombosis, granulocyte-macrophage-colony stimulating factor with interleukin-2 and, in renal cell carcinoma, 1892
Central neurocytoma, recurrent, chemotherapy for, 169
Centromeric instability, in meningioma, 440
c-erb B-2
amplification and overexpression of, in gastric cancer, prognosis and, 238 (letter)
in node-negative breast cancer, prognostic value of, 804
Cerebral glucose metabolism, after acute lymphoblastic leukemia, 693
Cerebrospinal fluid lactate dehydrogenase isoenzyme analysis, in CNS involvement in hematologic malignancies, 1599
Cervical cancer
Bax and Bcl-2 in, after radiotherapy with/without chemotherapy, 132
early-stage, parametrial invasion in, 2267
extraperitoneal aortic and common iliac dissection in, 1883
genetic susceptibility for, 2082
human papillomavirus-associated, in Hawaii, 1464
MN/CA9 in, 1108

- ovarian and nodal metastasis in, lymphovascular invasion and, 2578
 p27 and p53 in, radiotherapy response and, 2767
 radical trachelectomy for, 1877
 screening for, insurance coverage and, 2283, 2825
 Cervical intraepithelial neoplasia, photodetection of, 2275
 Chemoembolization
 hepatic arterial, for hepatocellular carcinoma, 1574
 for hepatocellular carcinoma, prognostic index for, 50
 Chemoradiotherapy
 for esophageal cancer, 988
 for head and neck cancer, vs. radiotherapy alone, 876
 Chemotherapy. *See also specific agents*
 for acute lymphoblastic leukemia, in second remission, 1166
 for acute myelogenous leukemia, 2037
 for adrenocortical carcinoma, 1159
 for bladder cancer, 1671
 for breast cancer, 1863, 2732
 in advanced disease, 375
 in early stage disease, 1417
 with isolated supraclavicular nodal metastases, 790
 in metastatic disease, 95, 124
 for carcinoid syndrome, 770
 for CNS prophylaxis, in acute lymphoblastic leukemia, 205
 febrile neutropenia and, oral ciprofloxacin for, 1710
 febrile neutropenia in
 oral ciprofloxacin for, 1710
 prophylactic cefixime for, 2849
 with fish oil, for canine lymphoma, 1917
 for gastric B-cell lymphoma, 1979
 for gliomas, after radiotherapy, 685
 with granulocyte-macrophage-colony stimulating factor, for neuroblastoma, 2839
 for hairy cell leukemia, 352
 hepatic arterial, for liver metastasis prevention, in colorectal cancer, 1549
 for hepatocellular carcinoma, National Cancer Data Base report on, 912
 for Hodgkin's disease
 in advanced disease, 2142
 granulocyte-macrophage-colony stimulating factor pretreatment and, 454
 intraarterial
 for astrocytomas, 2350
 with osmotic opening of blood-brain barrier, for brain tumors, 637
 intraperitoneal, intra-abdominal fibrosis after, 2447
 for islet cell carcinoma, 2194 (letter)
 for large cell lymphoma, in children, 166
 late effects of, in young adult survivors, 1667
 for lung cancer, 1353
 for mediastinal nonseminomatous germ cell tumors, 1051
 for melanoma, in advanced disease, 584
 for metastatic melanoma, 79
 myelosuppressive, bone marrow recovery in, FLT3-L as predictor of, 333
 neutropenia in, granulocyte-macrophage-colony stimulating factor for, morning vs. night administration of, 2033
 for nonsmall cell lung cancer, 318, 1045
 in advanced disease, 557
 in elderly, 2678
 onycholysis and, 2367
 for osteosarcoma of flat bones, 324
 for pancreatic cancer, 2505
 for prostate cancer
 in advanced disease, 825
 in metastatic hormone refractory disease, 1438
 with radiotherapy. *See Chemoradiotherapy*
 for recurrent central neurocytoma, 169
 for renal cell carcinoma, 1310
 for supratentorial primitive neuroectodermal tumors, 2189
 toxicity of, total body nitrogen in prediction of, 796
 Chernobyl nuclear accident, pediatric thyroid cancer and, duration of exposure and disease extent in, 1470
 Childbearing, after radical trachelectomy, for cervical cancer, 1877
 Childhood cancer. *See also specific cancers of childhood, e.g., Leukemia*
 late treatment effects of
 cardiovascular disease as, 2116
 in young adult survivors, 1667
 Children
 bone sarcomas of head and neck in, 2172
 cancer risk in, after in vitro fertilization, 2846
 chondrosarcoma of head and neck in, 2181
 febrile neutropenia in, prophylactic oral cefixime for, 2849
 hemangiopericytoma in, 198
 hematologic malignancies in. *See also Leukemia; Lymphoma*
 splenic rupture in, 480
 large cell lymphoma in, treatment of, 166
 T-cell-rich large B-cell lymphoma in, 2378
 China, quality of life assessment tool in, 1715
 Cholangiocellular cancer, primary hepatic, hepatitis C virus-related cirrhosis and, 2471
 Cholecystokinin-B receptor, in pancreatic cancer, 2487
 Chondromatous hamartomas, of lung, 964 (letter)
 Chondrosarcoma, of head and neck, in children, 2181
 CHOP regimen, for gastric B-cell lymphoma, 1979
 Chordoma, sacral, prognostic factors in, 2122
 Chromogranin A, in prostate cancer, 2590
 Chromosome abnormalities/translocations
 in 8p22, breast cancer prognosis and, 1410
 in 12p, acute lymphoblastic leukemia prognosis and, 1945
 in 13q14, in acute lymphoblastic leukemia, 1359
 in meningioma, 440

- t(16;21)(p11;q22), in acute myeloid leukemia, hemophagocytosis in, 1970
- t(8;21)(q22;q22), with granulocytic sarcoma, in acute myeloid leukemia, 1939
- Chronic leukemia. *See* Leukemia, chronic
- Chronic pancreatitis, ductal lesions in, *K-ras* mutations in, 2495
- Cigarette smoking, in cancer survivors, 674
- Ciprofloxacin, oral, for febrile neutropenia, 1710
- Cirrhosis, hepatitis C virus-related, primary cholangiocellular carcinoma of liver and, 2471
- Cisplatin
- for adrenocortical carcinoma, 1159
 - arterial chemoembolization with, for hepatocellular carcinoma, 1574
 - for bladder cancer, 1671
 - with granulocyte-macrophage-colony stimulating factor, for neuroblastoma, 2839
 - intraarterial, with interferon- α , for hepatocellular carcinoma, with portal vein thrombosis, 1986
 - for mediastinal nonseminomatous germ cell tumors, 1051
 - with paclitaxel, for breast cancer, 1863
 - for recurrent central neurocytoma, 169
- Clark level, in melanoma staging, 491 (editorial), 589
- Clear cell carcinoma, of ovary, clinical characteristics of, 2584
- Clinging carcinoma in situ, of breast, genetic abnormalities in, 2072
- Clodronate, oral, for bone metastases, 6
- c-met*
- amplification and overexpression of, in gastric cancer, prognosis and, 238 (letter)
 - in gastric cancer, 1801
- C/MOPP/ABV regimen, for Hodgkin's disease, 2142
- c-mpl*, in chronic myelogenous leukemia, 570
- Color Doppler ultrasonography, of ovarian cystic teratomas, 2298
- Colorectal cancer
- adenomatous polyposis coli I1307K mutation in, in Jews, 755
 - angiogenesis in, p53 and vascular endothelial growth factor and, 1820
 - carcinoembryonic antigen in, prognostic significance of, time-dependency of, 35
 - eosinophil count in, prognosis and, 1544
 - 5-fluorouracil for, small bowel toxicity of, 2425 (letter)
 - intraoperative floxuridine for, intra-abdominal fibrosis after, 2447
 - liver metastasis in, hepatic arterial 5-fluorouracil for prevention of, 1549
 - loss of heterozygosity in, 2661
 - multitargeted antifolate for, 1807
 - national report on, 2398
 - p53 in
 - prognostic significance of, time-dependency of, 35
 - survival and, 1814
 - pericolonic tumor deposits in, prognosis and, 2228
 - platelet-derived endothelial cell growth factor in, prognosis and, 42
 - preoperative tegafur suppositories for, 1007
 - prognostic factors in, American Joint Committee on Cancer and, 1739
 - quality of life in survivors of, 1294
 - telomerase activity in, metastasis and, 1304
 - Thomsen-Friedenreich antigen in, prognosis and, 1536
 - tissue factor expression in, hepatic metastasis and prognosis and, 295
- Common iliac dissection, extraperitoneal endoscopic, in cervical cancer, 1883
- Comorbid chronic disease, epidemiologic and therapeutic issues in, 663
- Comparative genomic hybridization, in esophageal cancer, nodal metastasis in, 268
- Complementary DNA libraries, 2
- Complementary health practices, with radiation therapy, for prostate cancer, 615
- Compliance, with cervical cancer screening, insurance coverage and, 2283, 2825
- Compression methods, for limb lymphedema, 2833
- Condylomata acuminata, squamous papilloma of urinary tract and, 1679
- Cranial irradiation
- cerebral glucose metabolism after, 693
 - for glioma, high-dose busulfan and thiopeta after, 685
- Cryoablation, for prostate cancer, sexual dysfunction and, 1454
- Cutaneous fibrosis, docetaxel and, 1078
- Cyclophosphamide
- for acute lymphoblastic leukemia, in second remission, 1166
 - for breast cancer, with isolated supraclavicular nodal metastases, 790
 - for gastric B-cell lymphoma, 1979
 - for Hodgkin's disease, 2142
 - for large cell lymphoma, in children, 166
 - for prostate cancer, in metastatic hormone refractory disease, 1438
 - for recurrent central neurocytoma, 169
 - toxicity of, total body nitrogen in prediction of, 796
- Cystectomy, outcome predictors for, 2327
- Cytarabine
- for acute lymphoblastic leukemia, in second remission, 1166
 - for acute myelogenous leukemia, 2037
 - for large cell lymphoma, in children, 166
- Cytochrome P450, in cervical cancer, genetic susceptibility and, 2082
- Cytoimplant immunotherapy, for pancreatic cancer, 1325

D

- Dacarbazine, for Hodgkin's disease, granulocyte-macrophage-colony stimulating factor pretreatment and, 454
- Daunomycin, for large cell lymphoma, in children, 166

- Daunorubicin, for acute lymphoblastic leukemia, in second remission, 1166
- Delirium, Memorial Delirium Assessment Scale for, 2860
- Deoxycoformycin, for hairy cell leukemia, 352
- Dermatofibrosarcoma protuberans, 2712
- Des-gamma-carboxy prothrombin
elevated, in hepatocellular carcinoma, 1557
enzyme immunoassay kit for, for hepatocellular carcinoma, 544
- Desmoid tumors, surgery vs. radiotherapy for, 1517
- Dexamethasone, for acute lymphoblastic leukemia, sepsis and, 1964
- Diarrhea, 5-fluorouracil-induced small bowel injury and, 2425 (letter)
- Diet
breast cancer and, 1239, 1245
in cancer survivors, 674
gastric cancer and, 737
- Diethylmaleate-mediated apoptosis, in prostate cancer, 2092
- Difluorodeoxycytidine. *See* Gemcitabine
- DNA content
in inverted urothelial papilloma, cancer risk and, 632
of renal cell carcinoma, prognosis and, 835
- cDNA libraries, 2
- DNA ploidy, in melanocytic skin lesions, 1370
- Docetaxel
cutaneous fibrosis and, 1078
for metastatic solid tumors, 180
for nonsmall cell lung cancer, 1045
- Docosahexaenoic acid, for doxorubicin-treated canine lymphoma, 1917
- Doxorubicin
with fish oil, for canine lymphoma, 1917
for gastric B-cell lymphoma, 1979
with granulocyte-macrophage-colony stimulating factor, for neuroblastoma, 2839
for Hodgkin's disease, 2142
granulocyte-macrophage-colony stimulating factor pretreatment and, 454
for islet cell carcinoma, 2194 (letter)
- Dry mouth, management of, 984
- Ductal carcinoma in situ, of breast. *See* Breast cancer, ductal in situ
- E**
- Economic status, breast cancer treatment and, 933
- Edmonton Symptom Assessment Scale, 2164
- Eicosapentaenoic acid, for doxorubicin-treated canine lymphoma, 1917
- EIF4E, in head and neck tumors, 2804
- 8p22 loss of heterogeneity, in breast cancer, prognosis and, 1410
- Elastic hosiery, for limb lymphedema, 2833
- Elderly
head and neck cancer in, accelerated radiotherapy for, 648
nonsmall cell lung cancer in, vinorelbine for, 2678
- Elective ipsilateral neck irradiation, for maxillary sinus cancer, 2246
- Embolization, transcatheter arterial, for hepatocellular carcinoma, prognostic index for, 50
- Emotional issues, in head and neck cancer, 2818
- Endocrine therapy
for breast cancer, in advanced disease, 95, 2047
for prostate cancer, 1445
sexual dysfunction and, 1454
- Endometrial cancer. *See also* Uterine cancer
altered Ig1/Ig2 expression in, 461
endometrioid vs. serous, molecular genetic pathways in, 814
hysteroscopy in, tumor dissemination via, 139
microsatellite instability in, frameshift mutations in, 2290
- Endometrial epithelia, GLUT1 staining in, 2775
- Endoscopic ultrasonographic staging, of esophageal cancer, treatment response prediction and, 1184 (letter)
- Endosonography, for esophageal cancer treatment response, 1798
- Enzyme immunoassay kit, for des-gamma-carboxy prothrombin, for hepatocellular carcinoma, 544
- Eosinophil count, in colorectal cancer, prognosis and, 1544
- Ependymoma, recurrent, stereotactic radiosurgery for, 870
- Epidermal growth factor receptor, in oligodendrogliomas, prognosis and, 862
- Epirubicin, for breast cancer, in advanced disease, 375
- Epithelial dysplasia, oral, MUC1 mucin in, 245
- Epithelioid sarcoma, paclitaxel for, 1614
- Erratum, 2889
- Esophageal cancer
in Barrett esophagus, intestinal metaplasia as precursor of, 2520
brachytherapy for, with chemotherapy, 988
carcinoma in situ, malignant potential of, telomerase activity and, 1524
diagnostic criteria for, in Japan vs. West, 969 (editorial), 996
early invasive, pathology of, 2429
Fas ligand in, 524
histopathology of, prognosis and, 1285
matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in, 2201
nodal metastasis in, predictors of, 1285
pretreatment endoscopic ultrasonographic staging of, treatment response prediction and, 1184 (letter)
quality of life in, 1781
small cell, surgery for, 262
squamous cell, nodal metastasis of, genetic aberrations and, 268
treatment response in, endosonographic assessment of, 1788
- Esophageal lesions, iodine-nonreactive, malignant potential of, telomerase activity and, 1524

- Essential thrombocytosis, transformed into leukemia, hematopoietic cell line with endothelial features from, 344
- Estramustine, for prostate cancer, in metastatic hormone refractory disease, 1438
- Estrogen receptors, in breast cancer, race and, 114
- Estrogen replacement therapy, lobular vs. ductal breast cancer and, 2570
- Ethanol injection, for hepatocellular carcinoma, intrahepatic recurrence after, 529
- Ethnicity
 - breast cancer and. *See under* Breast cancer
 - cancer incidence rates in, 2642
 - pain management and, 1929
- Ethno-oncology, breast cancer and, 1189
- Etidronate, oral, for bone metastases, 6
- Etoposide
 - for adrenocortical carcinoma, 1159
 - with granulocyte-macrophage-colony stimulating factor, for neuroblastoma, 2839
 - for mediastinal nonseminomatous germ cell tumors, 1051
- Ewing's sarcoma, of head and neck, in children, 2172
- Exercise
 - breast cancer and, 1248
 - in cancer survivors, 674
- Extended triple intrathecal therapy, for CNS prophylaxis, in acute lymphoblastic leukemia, 205
- Extramedullary plasmacytoma, occurrence and treatment of, 240 (letter)
- Extremity lymphedema, compression methods for, 2833
- Extremity sarcoma, postoperative surveillance after, 777

F

- FACT-G (Functional Assessment of Cancer Therapy-General) scale, for Chinese patients, 1715
- Familial lymphoma, registry-linked study of, 2357
- Fas ligand, in esophageal cancer, 524
- Fatigue, quality of life and, 1175
- Fatty acids, for doxorubicin-treated canine lymphoma, 1917
- Febrile neutropenia
 - oral ciprofloxacin for, 1710
 - prophylactic cefixime for, 2849
- Fertility, after radical trachelectomy, for cervical cancer, 1877
- α -Fetoprotein
 - vs. des-gamma-carboxy prothrombin, in hepatocellular carcinoma diagnosis, 544
 - at recurrence of germ cell tumors, 162
 - reduced, in hepatocellular carcinoma, 1557
- Fhit, in breast cancer, disease progression and, 1378
- FHIT, in gastric adenocarcinoma, 24
- Fiber, dietary
 - breast cancer and, 1239
 - gastric cancer and, 737
- Fibromatosis, aggressive, surgery vs. radiotherapy for, 1517

- Fibrosis, cutaneous, docetaxel and, 1078
- Field cancerization theory, metachronous head and neck tumors and, 884
- Fish oil, for canine lymphoma, 1917
- Flow cytometry
 - in bone marrow staging, in non-Hodgkin's lymphoma, 894
 - in inverted urothelial papilloma, cancer risk and, 632
 - in renal cell carcinoma, prognosis and, 835
- Floxuridine
 - intraperitoneal, intra-abdominal fibrosis after, 2447
 - for renal cell carcinoma, with biologic response modifiers, 1310
- FLT3-L, as predictor of bone marrow recovery in myelosuppressive therapy, 333
- Fluid hysteroscopy, for endometrial cancer, tumor dissemination via, 139
- Fluoropyrimidines, intraperitoneal, intra-abdominal fibrosis after, 2447
- 5-Fluorouracil, 2443
 - hepatic arterial, for liver metastasis prevention, in colorectal cancer, 1549
 - intrarectal, for colorectal cancer, apoptosis and angiogenesis and, 1007
 - postgastrectomy nodal distribution of, 2443
 - toxicity of
 - small bowel, 2425 (letter)
 - total body nitrogen in prediction of, 796
- Foot, giant cell tumors of, 2022
- Frameshift mutations
 - in endometrial cancer, microsatellite instability and, 2290
 - in hepatocellular carcinoma, in Japan, 1025
- Functional Assessment of Cancer Therapy-General (FACT-G) scale, for Chinese patients, 1715

G

- Gallbladder cancer, N-myristoyltransferase in, 1992
- Gangliosides, in pancreatic cancer, as immunotherapy targets, 1828
- Gastrectomy
 - 5-fluorouracil distribution to lymph nodes after, 2443
 - survival after, National Cancer Data Base report on, 921
- Gastric B-cell lymphoma, CHOP regimen for, 1979
- Gastric cancer
 - c-*met* and c-*erb* B-2 overexpression and amplification in, prognosis and, 238 (letter)
 - diet and, 737
 - early-stage, lymph node morphometry in, 2438
 - familial factors in, *H. pylori* infection and, 274
 - FHIT in, 24
 - gastrectomy for
 - 5-fluorouracil distribution after, 2443
 - survival after, National Cancer Data Base report on, 921
- Goeski classification of, 2426 (letter)
- MG7-Ag in, immunopolymerase chain reaction for, 280
- natural killer cells in, prognosis and, 577

risk of, *H. pylori* and, anti-CagA antibody in risk assessment for, 1530
stage-stratified survival in, National Cancer Data Base report on, 921
staging of, 1763 (editorial), 1797
thymidine phosphorylase in, 2220
TPR-MET rearrangements in, 1801
Gastric cardia adenocarcinoma, intestinal metaplasia as precursor of, 2520
Gastric lymphoma, MALT, clinicopathology of, 2210
Gastrin, in pancreatic cancer, 2487
Gastrin-releasing peptide antagonists, for breast cancer, 1384
Gastrointestinal sarcoma, recurrent, salvage surgery for, 66
Gemcitabine
 for lung cancer, 1353
 for metastatic pancreatic cancer, 2505
 for metastatic solid tumors, 180
 for nonsmall cell lung cancer, in advanced disease, 557
Genetics, advances in, 2
Genital warts, squamous papilloma of urinary tract and, 1679
Genomic hybridization, in esophageal cancer, nodal metastasis in, 268
Genomics, 2
Germ cell tumors
 mediastinal nonseminomatous, survival in, 1051
 second nongerminal cancer and, 2629
 tumor markers at recurrence of, 162
Giant cell tumors, of hand and foot, 2022
Glioblastoma, supratentorial, WHO classification of, 1477
Glioblastoma multiforme
 brachytherapy for, 2797
 hypoxia-inducible factor 1 α in, 2606
Glioma
 diagnostic discrepancies in, 2342
 hypoxia-inducible factor 1 α in, 2606
 radiotherapy for, high-dose busulfan and thiopetafter, 685
Glucose metabolism, cerebral, after acute lymphoblastic leukemia, 693
GLUT1 staining, in endometrial epithelia, 2775
Glutathione-depletion-mediated apoptosis, in prostate cancer, 2092
Glutathione-S-transferase, in cervical cancer, genetic susceptibility and, 2082
Glyco-nitric oxide conjugate, for breast cancer, 381
Glycoprotein 130, in breast cancer, prognosis and, 369
Glycosyltransferase, in pancreatic cancer, 1037
Goeski classification, for gastric cancer, 2426 (letter)
Gonadotropin-releasing hormone analogues, for prostate cancer, 1445
Grading, of papillary thyroid cancer, 1766 (editorial), 1902
Granulocyte-macrophage-colony stimulating factor
 with chemotherapy, for neuroblastoma, 2839
 for Hodgkin's disease, 454
 for renal cell carcinoma, 1317, 1892

 for soft tissue/bone sarcoma, morning vs. night administration of, 2033
Granulocytic sarcoma, with t(8;21)(q22;q22), in acute myeloid leukemia, 1939
Gynecologic cancer. *See also specific types*
 altered Ig1/Ig2 expression in, 461

H

Hairy cell leukemia, deoxycoformycin for, 352
Hamartomas, chondromatous, of lung, 964 (letter)
Hand, giant cell tumors of, 2022
Hawaii, human papillomavirus-associated cancer in, 1464
Head and neck cancer. *See also* Oral cancer
 accelerated radiotherapy for, in elderly, 648
 bone sarcomas, in children, 2172
 chondrosarcoma, in children, 2181
 eIF4E in, 2804
 epidemiology of, in Canada and U.S., 1728
 newly diagnosed, psychologic distress in, 2818
 origins of multiple tumors in, 884
 paragangliomas, growth rate of, treatment decisions and, 2812
 radiotherapy with/without chemotherapy for, 876
Health behaviors, of cancer survivors, 674
Health insurance, cervical cancer screening compliance and, 2283, 2825
Heart rate variability, impaired, paclitaxel-induced, 2149
Heat shock protein-27, in hepatocellular carcinoma, prognosis and, 2464
Helicobacter pylori, gastric cancer and
 anti-CagA antibody and, 1530
 familial factors in, 274
Hemangioblastoma, hypoxia-inducible factor 1 α in, 2606
Hemangiopericytoma, in infants and children, 198
Hematologic malignancies, CNS involvement in, CSF lactate dehydrogenase isoenzyme analysis for, 1599
Hematopoietic cell line, with endothelial features, from transformed myeloproliferative syndrome, 344
Hemophagocytosis, in acute myeloid leukemia, with t(16;21)(p11;q22), 1970
Hepatic arterial chemoembolization, for hepatocellular carcinoma, 1574
Hepatic artery embolization, transcatheter, for hepatocellular carcinoma, prognostic index for, 50
Hepatic cancer, primary cholangiocellular, hepatitis C virus-related cirrhosis and, 2471
Hepatic metastasis
 in colorectal cancer
 hepatic arterial 5-fluorouracil for prevention of, 1549
 tissue factor and, 295
 percutaneous microwave coagulation therapy for, 302
Hepatic nodules, precancerous, telomerase in, 312
Hepatic tumors, radiofrequency ablation of, 2452
Hepatitis B-related hepatocellular carcinoma, recurrence of, virus-related factors in, 1016
Hepatitis B virus DNA, in hepatocellular carcinoma in hepatitis C-infected patients, 2478

Hepatitis C, interferon- α retreatment for, hepatocellular carcinoma after, 58

Hepatitis C virus-related cirrhosis, primary cholangiocellular carcinoma of liver and, 2471

Hepatitis C virus-related hepatocellular carcinoma, hepatitis B virus DNA in, 2478

Hepatocellular carcinoma

- ethanol injection for, intrahepatic recurrence after, 529
- frameshift mutations in, in Japan, 1025
- heat shock protein-27 in, prognosis and, 2464
- hepatitis B-related, recurrence of, virus-related factors in, 1016
- in hepatitis C-infected patients, hepatitis B virus DNA in, 2478
- hepatoma specific gamma-glutamyl transferase in, 761
- heterozygous alpha-1-antitrypsin deficiency type PiZ and, 2669
- high plasma des-gamma-carboxy prothrombin and low serum α -fetoprotein in, 1557
- after interferon- α retreatment for hepatitis C, 58
- p53 mutations in, in India, 1565
- percutaneous microwave coagulation therapy for, 302
- with portal vein thrombosis, interferon- α and intraarterial cisplatin for, 1986
- precancerous nodules in, telomerase in, 312
- radiofrequency tumor ablation in, 2452
- revised enzyme immunoassay kit for des-gamma-carboxy prothrombin for, 544
- transcatheter arterial chemoembolization for, 1574
- prognostic index for, 50
- treatment of, National Cancer Data Base report on, 912
- vinyl chloride-related, p53 mutation in, 1030

Hepatoid carcinoma of pancreas, 1582

Hepatoma

- heterozygous alpha-1-antitrypsin deficiency type PiZ and, 2669
- pathologic TNM staging system for, 538
- percutaneous microwave coagulation therapy for, 302

Hepatoma specific gamma-glutamyl transferase, in hepatocellular carcinoma, 761

Herbal remedies, with radiation therapy, for prostate cancer, 615

Hispanics

- cancer incidence rates in, 2642
- pain management for, 1929

HIV infection. *See* Human immunodeficiency virus infection

hMSH2, in urothelial cancer, 2333

Hodgkin's disease. *See also* Lymphoma

- C/MOPP/ABV regimen for, 2142
- CNS involvement in, CSF lactate dehydrogenase isoenzyme analysis for, 1599
- granulocyte-macrophage-colony stimulating factor for, 454
- HIV-negative Kaposi sarcoma and, 708 (letter)
- registry-linked study of, 2357

Holleb, Arthur I., tribute to, 2653

Hormonal factors

- in breast cancer, 1230
- in soft tissue sarcoma, 786

Hormonal therapy

- for breast cancer, in advanced disease, 95, 2047
- for prostate cancer, 1445
- sexual dysfunction and, 1454

Hormone receptors, in breast cancer, race and, 114

Hormone replacement therapy, lobular vs. ductal breast cancer and, 2570

Hosiery, for limb lymphedema, 2833

Hospital Anxiety and Depression Scale (HADS), in head and neck cancer, 2818

H-ras mutations, in mucoepidermoid salivary gland cancer, 518

Human chorionic gonadotropin

- in pancreatic cancer, 1037
- at recurrence of germ cell tumors, 162

Human herpesvirus-8

- classic Kaposi's sarcoma and, 500
- Kaposi sarcoma of salivary glands and, 15

Human immunodeficiency virus infection

- lung cancer in, 563
- anti-CD4 antibody and, 468
- non-Hodgkin's lymphoma in, antiretroviral therapy effects in, 1696

Human kallikrein-2, in prostate cancer, UICC workshop on, 955

Human mismatch repair gene hMSH2, in urothelial cancer, 2333

Human papillomavirus, lung cancer and, 1347

Human papillomavirus-associated cancer

- in Asian and Pacific Islanders, 1464
- MVA E2 virus for, 1650

Hybrid Capture II assay, for human papillomavirus, in lung cancer, 1347

Hydroxyurea, for large cell lymphoma, in children, 166

Hyperthermia, with mitomycin C, for peritoneal carcinomatosis, 2512

Hyposalivation, management of, 984

Hypoxia-inducible factor 1 α , in brain tumors, 2606

Hysteroscopy, for endometrial cancer, tumor dissemination via, 139

I

Ibandronate, oral, for bone metastases, 6

Ifosfamide

- for bladder cancer, 1671
- with granulocyte-macrophage-colony stimulating factor, for neuroblastoma, 2839

Immunopolymerase chain reaction, for MG7-Ag, in gastric cancer, 280

Immunosuppression, alcohol-related, nonsmall cell lung cancer and, 468

Immunotherapy

- for chronic myelogenous leukemia, thrombopoietin and c-mpl expression and, 570
- cytoimplant, for pancreatic cancer, 1325

- with floxuridine, for renal cell carcinoma, 1310
- lymph node dissection and, 175
- for pancreatic cancer, 1325
- gangliosides targets for, 1828
- for renal cell carcinoma, granulocyte-macrophage-colony stimulating factor in, 1317
- Incontinence, after prostate cancer, 1454
- India, p53 mutations in hepatocellular carcinoma in, 1565
- Infants. *See also* Children
 - hemangiopericytoma in, 198
 - leukemia in, insulin-like growth factor-2 in, 2372
- Insulin-like growth factor-2, in infant leukemia and childhood neuroblastoma, 2372
- Insurance, cervical cancer screening compliance and, 2283, 2825
- Interferon- α
 - for chronic myelogenous leukemia, thrombopoietin and c-mpl expression and, 570
 - with granulocyte-macrophage-colony stimulating factor, for renal cell carcinoma, 1317
 - for hepatitis C retreatment, hepatocellular carcinoma after, 58
 - with intraarterial cisplatin, for hepatocellular carcinoma, with portal vein thrombosis, 1986
- Interferon, with floxuridine, for renal cell carcinoma, 1310
- Interferon-2a, with interleukin-2, for metastatic melanoma, 1703
- Interleukin-2
 - with floxuridine, for renal cell carcinoma, 1310
 - with granulocyte-macrophage-colony stimulating factor, for renal cell carcinoma, 1317, 1892
 - with interferon-2a, for metastatic melanoma, 1703
 - for lung metastasis, in melanoma, 2042
- Interleukin-6, in breast cancer, prognosis and, 369
- International Society of Urologic Pathology, classification and grading system for bladder tumors, 1509, 1513
- International Union Against Cancer, Prostate Cancer Tumor Marker Workshop of, 955
- International Union Against Cancer/American Joint Committee on Cancer, gastric cancer staging system of, 1763 (editorial)
- Intestinal metaplasia, as precursor of Barrett esophagus adenocarcinoma and gastric cardia adenocarcinoma, 2520
- Intra-abdominal fibrosis, after intraperitoneal floxuridine, 2447
- Intraperitoneal chemohyperthermia, with mitomycin C, for peritoneal carcinomatosis, 2512
- Inverted urothelial papilloma, cancer risk with, predictors of, 632
- In vitro fertilization, pediatric cancer risk and, 2846
- Islet cell carcinoma, doxorubicin and streptozocin for, 2194 (letter)
- Italy, melanoma risk factors in, 2704

J

- Japan
 - esophageal cancer in, diagnostic criteria for, 969 (editorial), 996
 - hepatocellular carcinoma in, frameshift mutations and, 1025
- Japanese Americans, gastric cancer in, stage-stratified survival in, 921
- Jews, adenomatous polyposis coli I1307K mutation in, 755

K

- Kallikrein, in prostate cancer, UICC workshop on, 955
- Kaposi sarcoma
 - classic, epidemiology of and risk factors for, 500
 - HIV-negative, lymphoproliferative disorders and, 708 (letter)
 - of salivary glands, 15
- K-ras mutations
 - in ductal lesions in chronic pancreatitis, 2495
 - in endometrial cancer, 814

L

- Lactate dehydrogenase, at recurrence of germ cell tumors, 162
- Lactate dehydrogenase isoenzyme, in cerebrospinal fluid, CNS involvement in hematologic malignancies and, 1599
- Lanreotide, for carcinoid syndrome, 770
- Laser capture microdissection, 2
 - of metastatic skin tumors, 749
- Latinos
 - cancer incidence rates in, 2642
 - pain management for, 1929
- Leg, lymphedema of, compression methods for, 2833
- Leiomyosarcoma, testicular, after high-dose oral-turbinol, 2195 (letter)
- Leukemia
 - acute, with serosal involvement, CA 125 in, 75
 - acute lymphoblastic
 - abnormal 12p in, prognosis and, 1945
 - ATM gene deletion in, in adults, 1057
 - cerebral glucose metabolism after, 693
 - CNS prophylaxis for, with extended triple intrathecal therapy and modified BFM chemotherapy, 205
 - dexamethasone for, sepsis and, 1964
 - in second remission, treatment and survival in, 1166
 - 13q14 deletions in, 1359
 - acute myeloid
 - CD34 in, prognosis and, 2529
 - recurrent/refractory, mitoxantrone and cytarabine for, 2037
 - after strontium-89 for prostate cancer, 620
 - with t(16;21)(p11;q22), hemophagocytosis in, 1970
 - with t(8;21)(q22;q22) and granulocytic sarcoma, 1939
 - bone marrow necrosis in, 1769
 - chronic myelogenous, thrombopoietin and c-mpl expression in, 570

- CNS involvement in, CSF lactate dehydrogenase isoenzyme analysis for, 1599
- hairy cell, deoxycoformycin for, 352
- hematopoietic cell line with endothelial features from, 344
- HIV-negative Kaposi sarcoma and, 708 (letter)
- in infants, insulin-like growth factor-2 in, 2372
- secondary, 497 (editorial)
- splenic rupture in, 480
- Lifestyle changes, by cancer survivors, 674
- Li-Fraumeni syndrome, brain tumors in, 433
- Limb lymphedema, compression methods for, 2833
- Limb sarcoma, postoperative surveillance for, 777
- Liver. *See under* Hepatic; Hepatocellular
- Loss of heterozygosity
- in colorectal cancer, 2661
 - origins of metachronous head and neck tumors and, 884
- Loss of heterozygosity analysis, 2
- Lumpectomy, for mammographically detected ductal in situ carcinoma, local recurrence after, 596
- Lung
- carcinoid tumors of, p16^{INK4A} and retinoblastoma proteins in, 550
 - multiple chondromatous hamartomas of, 964 (letter)
 - neuroendocrine tumors of, p16^{INK4A} and retinoblastoma proteins in, 550
- Lung cancer
- adenocarcinoma, in young patients, 1837
 - in HIV infection, 468, 563
 - human papillomavirus and, 1347
 - mast cell density in, prognosis and, 2687
 - nonsmall cell
 - anti-CD4 antibody in, alcohol use and, 468
 - docetaxel and vinorelbine for, 1045
 - gemcitabine and vinorelbine for, 557, 1353
 - treatment of, practice patterns in, 1336
 - UFT plus cisplatin for, 318
 - vinorelbine for, in elderly, 2678 - small cell, p16^{INK4A} and retinoblastoma proteins in, 550
- Lung metastasis, in melanoma, interleukin-2 for, 2042
- Lung perfusion scans, in prediction of radiation-induced changes in pulmonary function tests, 2135
- Lymphedema, compression methods for, 2833
- Lymph node(s)
- 5-fluorouracil distribution to, postgastrectomy, 2443
 - in gastric cancer, morphometry of, 2438
 - sentinel, in breast cancer, pathologic analysis of, 971 (editorial)
 - uninvolved
 - in breast cancer, number of, prognosis and, 114
 - management of, 175
- Lymph node analysis, in prediction of calcitonin normalization, in medullary thyroid cancer, 1909
- Lymph node biopsy, in breast cancer
- accuracy of in large tumors, 2540
 - with lymphoscintigraphy, 2546
 - morbidity after, vs. with axillary node dissection, 608
 - pathologic findings in, 971 (editorial), 1099
- Lymph node dissection
- axillary, in breast cancer, 1852
 - extraperitoneal endoscopic, in cervical cancer, 1883
 - immunotherapy and, 175
- Lymph node metastasis. *See also* Metastasis
- in breast cancer
 - isolated supraclavicular, chemotherapy and bone marrow transplant for, 790
 - sentinel node pathology and, 1099 - in cervical cancer
 - in early-stage disease, 2267
 - lymphovascular invasion and, 2578 - in esophageal cancer
 - genetic abnormalities and, 268
 - predictors of, 1285 - in gastric cancer, morphometry of, 2438
 - in melanoma, ultrasonography of, 2534
 - in prostate cancer, artificial intelligence in prediction of, 2105
- Lymphoma
- bone marrow staging in, by flow cytometry, 894
 - CNS involvement in, CSF lactate dehydrogenase isoenzyme analysis for, 1599
 - familial, registry-linked study of, 2357
 - fish oil for, in dogs, 1917
 - gastric B-cell, CHOP regimen for, 1979
 - in HIV infection, antiretroviral therapy effects in, 1696
 - HIV-negative Kaposi sarcoma and, 708 (letter)
 - Hodgkin's. *See* Hodgkin's disease
 - large cell, pediatric, chemotherapy for, 186
 - MALT
 - CHOP regimen for, 1979
 - gastric, clinicopathology of, 2210
 - small intestinal, prognosis in, 286
 - of small intestine, prognosis in, 286 - pediatric, splenic rupture in, 480
 - T-cell-rich large B-cell, in children and adolescents, 2378
 - testicular, extranodal recurrence of, 154
- Lymphoproliferative disorders, HIV-negative Kaposi sarcoma and, 708 (letter)
- Lymphoscintigraphy, in sentinel node biopsy, in breast cancer, 2546

M

- Mad1 protein, in breast cancer, 1623
- Malignant fibrous histiocytoma, of head and neck, in children, 2172
- Malignant melanoma. *See* Melanoma
- MALT lymphoma
- CHOP regimen for, 1979
 - gastric, clinicopathology of, 2210
 - small intestinal, prognosis in, 286
- Mammography
- disease outcome and, 1756 (letter)
 - intervals for, 1282

- Managed care
cervical cancer screening compliance and, 2283, 2825
oncology services purchasing recommendations for, 2877
- Mast cell density, in lung cancer, prognosis and, 2687
- Matrix metalloproteinase 7 and 9, in esophageal cancer, 2201
- Maxillary sinus cancer, elective ipsilateral neck irradiation for, 2246
- Mechlorethamine, for Hodgkin's disease, granulocyte-macrophage-colony stimulating factor pretreatment and, 454
- Mediastinal nonseminomatous germ cell tumors, survival in, 1051
- Medroxyprogesterone acetate, for pancreatic cancer, 2000
- Megestrol acetate, standard vs. high dose, for advanced prostate cancer, 825
- Melanocytic nevi, melanoma risk and, 2704
- Melanocytic skin lesions, DNA ploidy and abnormality in, 1370
- Melanoma
advanced, vinorelbine and tamoxifen for, 584
DNA ploidy and abnormality in, 1370
histopathology of, 491 (editorial)
local recurrence of, prognosis and disease progression after, 1063
locoregional metastasis in, ultrasound detection of, 2534
lung metastasis in, interleukin-2 for, 2042
metastatic
interleukin-2 with interferon-2a for, 1703
R₂₄ anti-Gd3 monoclonal antibody for, 2694
mythology and numerology of, 491 (editorial)
postoperative hyperfractionated radiation therapy for, 88
revised American Joint Committee on Cancer Staging system for, 1484
risk factors for, 2704
staging of
American Joint Committee on Cancer Staging revised system for, 1484
Clark levels in, 491 (editorial), 589
Membrane type 1-matrix metalloproteinase, in esophageal cancer, 2201
- Memorial Delirium Assessment Scale, 2860
- Meningioma, chromosome instability in, 440
- Menstrual factors, in soft tissue sarcoma, 786
- Merkel cell carcinoma, 1842
- MET, in pancreatic cancer, 1037
- Metastasis
bone
oral Bisphosphonates for, 6
pamidronate for, in breast cancer, 1082
primary site determination for, 1759 (letter)
bone marrow, in breast cancer, in first recurrence, 2252
in breast cancer, survival and, 95
in colorectal cancer, telomerase activity and, 1304
hepatic
in colorectal cancer
hepatic arterial 5-fluorouracil for prevention of, 1549
tissue factor and, 295
percutaneous microwave coagulation therapy for, 302
laser capture microdissection of, 749
lung, in melanoma, interleukin-2 for, 2042
lymph node. *See also under* Lymph node
in breast cancer, sentinel node pathology and, 1099
in cervical cancer
in early-stage disease, 2267
lymphovascular invasion and, 2578
in esophageal cancer
genetic abnormalities and, 268
predictors of, 1285
in gastric cancer, morphometry of, 2438
isolated supraclavicular, in breast cancer, chemotherapy and bone marrow transplant for, 790
in melanoma, ultrasonography of, 2534
in prostate cancer, artificial intelligence in prediction of, 2105
in melanoma, ultrasound detection of, 2534
ovarian, in cervical cancer, lymphovascular invasion and, 2578
in pancreatic cancer, reverse-transcriptase PCR detection of, 1037
in prostate cancer, 2788
retroperitoneal, from extremity soft tissue sarcoma, 364
testicular, in neuroblastoma, 2636
- Methotrexate
for large cell lymphoma, in children, 166
toxicity of, total body nitrogen in prediction of, 796
- Mexican Americans
cancer incidence rates in, 2642
pain management for, 1929
- MG7-Ag, in gastric cancer, immunopolymerase chain reaction for, 280
- MIB-1
in bladder cancer, prognosis and, 2598
in inverted urothelial papilloma, cancer risk and, 632
in oligodendrogliomas, prognosis and, 862
- Microdissection, 2
- Micrometastasis, bone marrow, in breast cancer, in first recurrence, 2252
- Microsatellite instability, in endometrial cancer, 814
frameshift mutations in, 2290
- Microwave coagulation therapy, for hepatic tumors, 302
- Migration patterns, breast cancer and, 1203
- Minorities
breast cancer survival in, 114
cancer incidence rates in, 2642
pain management for, 1929
- Mitomycin C, intraperitoneal chemohyperthermia with, for peritoneal carcinomatosis, 2512
- Mitotane, for adrenocortical carcinoma, 711, 1159
- Mitotic index, in oligodendrogliomas, prognosis and, 862

Mitoxantrone
for acute myelogenous leukemia, 2037
for breast cancer, with isolated supraclavicular nodal metastases, 790
MN/CA9, in Papanicolaou smear, as dysplasia/neoplasia marker, 1108
Modified vaccinia virus Ankara for human papillomavirus-related cancers, 1650
Mohs micrographic surgery
for basal cell carcinoma, perineural spread after, 1605
for Merkel cell carcinoma, 1842
Monoclonal antibody, R₂₄ anti-Gd3, for metastatic melanoma, 2694
MUC1 mucin, in premalignant oral lesions and oral cancer, 245
Mucoepidermoid salivary gland cancer, H-ras mutations in, 518
Mucosa-associated lymphoid tissue lymphoma. *See* MALT lymphoma
Multiple myeloma, oral Bisphosphonates for, 6
Multitargeted antifolate LY231514, for colorectal cancer, 1807
Murphy, Gerald P., tribute to, xx (March 1)
MVA E2 virus, for human papillomavirus-related cancers, 1650
Myc protein, in breast cancer, 1623
Myeloproliferative syndrome, hematopoietic cell line with endothelial features from, 344
Myelosuppressive therapy, bone marrow recovery in, FLT3-L as predictor of, 333
Myelotoxicity, of cyclophosphamide, methotrexate and 5-fluorouracil, total body nitrogen in prediction of, 796
N-Myristoyltransferase, in gallbladder cancer, 1992

N

n-3 fatty acids, for doxorubicin-treated canine lymphoma, 1917
Nasopharyngeal cancer, metastatic, vascular endothelial growth factor in, 255
National Action Plan of Breast Cancer, Workshop on Multicultural Aspects of Cancer Etiology, March 1 Supplement
National Cancer Data Base report
on breast cancer treatment in low-income patients, 933
on hepatocellular carcinoma treatment, 912
on stage-stratified survival in gastric carcinoma, 921
National Cancer Institute, national report on cancer of, 2398
National Surgical Adjuvant Breast Project
pathologic findings in intraductal carcinoma, 1976 (letter)
Protocol B-17 of, 242 (letter)
Native Americans, breast cancer in
migration patterns and, 1203
urban environment and, 1207
Natural killer cells, in gastric cancer, prognosis and, 577
Needs assessment

for cancer patients, 217
for palliative care, 900
Nephrogenic metaplasia, with cytologic atypia, 853
Neuroblastoma
chemotherapy with granulocyte-macrophage-colony stimulating factor for, 2839
insulin-like growth factor-2 in, 2372
multifocal, biology and surgery of, 1955
testicular/paratesticular involvement in, 2636
Neurocytoma, central, recurrent, chemotherapy for, 169
Neuroectodermal tumors, supratentorial primitive, treatment of, 2189
Neuroendocrine markers, in prostate cancer, UICC workshop on, 955
Neuroendocrine tumors, of lung, p16^{INK4A} and retinoblastoma proteins in, 550
Neuron specific enolase, in prostate cancer, 2590
Neurotoxicity, of granulocyte-macrophage-colony stimulating factor with interleukin-2, 1892
Neutropenia
febrile
oral ciprofloxacin for, 1710
prophylactic cefixime for, 2849
granulocyte-macrophage-colony stimulating factor for, morning vs. night administration of, 2033
Nevi, melanocytic
DNA ploidy and abnormality in, 1370
melanoma risk and, 2704
Nitric oxide, for ovarian cancer, 381
Nitrogen index, as chemotherapy toxicity predictor, 796
S-Nitroso-N-acetyl-penicillamine, for ovarian cancer, 381
Nodal metastasis. *See* Lymph node metastasis
Non-Hodgkin's lymphoma. *See* Lymphoma
Nutrition
breast cancer and, 1239, 1245
in cancer survivors, 674
gastric cancer and, 737

O

Obesity
android, breast cancer survival and, 2752
breast cancer risk and, 1248
Octreotide, for carcinoid syndrome, 770
Oligodendroglioma, grade 2, prognostic factors in, 862
Olpadronate, oral, for bone metastases, 6
Oncology services, purchasing recommendations for, 2877
Onycholysis, chemotherapy and, 2367
Oral cancer. *See also* Head and neck cancer
screening for, community-based, cluster-randomized program for, 664
squamous cell, MUC1 mucin in, 245
Oral epithelial dysplasia, MUC1 mucin in, 245
Osteosarcoma
of flat bones, 324
granulocyte-macrophage-colony stimulating factor for, morning vs. night administration of, 2033
of head and neck, in children, 2172

- Ovarian cancer
 advanced epithelial, cytoreductive surgery with
 rectosigmoid colon reconstruction for, 389
 altered Ig1/Ig2 expression in, 461
 clear cell, clinical characteristics of, 2584
 epithelial, ascitic p53 autoantibodies in, 1432
 germ cell
 second nongermlinal cancer in, 2629
 tumor markers at recurrence of, 162
 glyco-nitric oxide conjugate for, 381
 recurrent epithelial, secondary cytoreductive surgery
 for, 144
 synucleins expression in, 2154
 ultrasonographic characterization of, 2298
Ovarian cystic teratomas, ultrasonographic characteriza-
 tion of, 2298
Ovarian metastasis, in cervical cancer, lymphovascular
 invasion and, 2578
Ovarian tumors, premalignant, synucleins expression in,
 2154
- P**
- p16, in prostate cancer, prognosis and, 416
p16^{INK4A}, in pulmonary neuroendocrine tumors, 550
p53
 in ascitic fluid, in ovarian cancer, 1432
 in breast cancer, with ipsilateral recurrence, 1091
 in cervical cancer, genetic susceptibility and, 2082
 in colorectal cancer
 angiogenesis and, 1820
 prognostic significance of, time-dependency of, 35
 survival and, 1814
 in endometrial cancer, 814
 in gastric MALT lymphoma, 2210
 in hepatocellular carcinoma, in India, 1565
 in inverted urothelial papilloma, cancer risk and, 632
 in node-negative breast cancer, prognostic value of,
 804
 origins of metachronous head and neck tumors and,
 884
 in vinyl chloride-related hepatocellular carcinoma,
 1030
Paclitaxel
 apoptosis and, mechanisms of, 2619
 for bladder cancer, 1671
 cardiotoxicity of, 2149
 with cisplatin, for breast cancer, 1863
 for epithelioid sarcoma, 1614
 for metastatic breast cancer, 124
 for metastatic melanoma, 79
 onycholysis and, 2367
 with vinorelbine, for breast cancer, 2732
Pain, quality of life and, 1175
Pain diary, for ambulatory patients, 2387
Pain management, for minority patients, 1929
Palliative care
 needs assessment for, 900
 pain diary in, 2387
 Schedule of Attitudes toward Hastened Death in, 2869
Pamidronate
 for bone metastasis, in breast cancer, 1082
 oral, for bone metastases, 6
Pancreatic cancer
 allogeneic mixed lymphocyte culture for, 1325
 gangliosides in, as immunotherapy targets, 1828
 gastrin in, 2487
 gemcitabine for, 2505
 hepatoid, 1582
 medroxyprogesterone acetate for, 2000
 metastatic cell detection in, by reverse-transcriptase
 PCR, 1037
 tumor markers for, 1037
 UK Pan-1 cell line for, 2010
 vascular endothelial growth factor in, 2239
Pancreatitis, chronic, ductal lesions in, *K-ras* mutations
 in, 2495
Papanicolaou smear
 MN/CA9 in, as dysplasia/neoplasia marker, 1108
 patient use of, insurance coverage and, 2283, 2825
Papilloma, inverted urothelial, cancer risk with, predic-
 tors of, 632
Papilloma E2 gene, in MVA E2 virus, 1650
Paraganglioma
 of bladder, 844
 of head and neck, growth rate of, treatment decisions
 and, 2812
Paratesticular metastasis, in neuroblastoma, 2636
Patient. *See under Cancer*
Pediatric cancer. *See Children*
Pemetrexed disodium, for colorectal cancer, 1807
Penile cancer, human papillomavirus-associated, in Ha-
 waii, 1464
Percutaneous ethanol injection, for hepatocellular carci-
 noma, intrahepatic recurrence after, 529
Percutaneous microwave coagulation therapy, for he-
 patic tumors, 302
Pericolonic tumor deposits, in colorectal cancer, progn-
 osis and, 2228
Peripheral blood stem cells, negative purging of, in breast
 cancer, 2754
Peritoneal carcinomatosis
 intraperitoneal chemohyperthermia with mitomycin C
 for, 2512
 nongynecologic
 clinicopathology of, 358
 treatment and survival in, 358
Peritoneal fibrosis, after intraperitoneal floxuridine, 2447
Photodetection, of cervical intraepithelial neoplasia, 2275
Physician, as cancer patient, 2199
Physician-assisted suicide, Schedule of Attitudes toward
 Hastened Death for, 2869
Phytoestrogens, breast cancer and, 1239, 1245
Pigmentation, melanoma risk and, 2704
Piz type alpha-1-antitrypsin deficiency, hepatic cancer
 and, 2669

Plasmacytoma, extramedullary, occurrence and treatment of, 240 (letter)

Platelet-derived endothelial cell growth factor, in colorectal cancer, prognosis and, 42

Pleuropulmonary blastoma, transition from type 1 to type III in, 2854

Ploidy
in inverted urothelial papilloma, cancer risk and, 632
in renal cell carcinoma, prognosis and, 835

Polyacrylamide gel electrophoresis, 2

Polymerase chain reaction, reverse-transcriptase, for metastatic pancreatic cancer, 1037

Population-based research, in breast cancer, community involvement in, 1214

Poverty, breast cancer and, 933, 1256

Prednisone
vs. dexamethasone, for acute lymphoblastic leukemia, sepsis and, 1964
for gastric B-cell lymphoma, 1979
for Hodgkin's disease, 2142
for large cell lymphoma, in children, 166

Preferred provider organizations, cervical cancer screening compliance and, 2283, 2825

Pregnancy
age at first, soft tissue sarcoma and, 786
via in vitro fertilization, pediatric cancer risk and, 2846

Primitive neuroectodermal tumors, supratentorial, treatment of, 2189

Procarbazine, for Hodgkin's disease, 2142
granulocyte-macrophage-colony stimulating factor pretreatment and, 454

Progesterone receptors, in breast cancer, race and, 114

Proliferating cell nuclear antigen
in gastric MALT lymphoma, 2210
in oligodendrogliomas, prognosis and, 862

Prostate cancer
advanced, standard vs. high dose megestrol acetate for, 825
androgen deprivation therapy for, prostate specific membrane antigen expression after, 407
artificial neural networks, UICC workshop on, 955
bone metastasis in, oral Bisphosphonates for, 6
CDK4 in, prognosis and, 416
chromogranin A in, 2590
circulating cancer cells in, identification of, 2788
current health practices and willingness to make lifestyle change in, 674
incidence and treatment of, in Sweden, 1445
localized, treatment selection for, 1122
lymph node metastasis in, artificial intelligence in prediction of, 2105
metastasis in, 2788
metastatic hormone refractory, estramustine and cyclophosphamide for, 1438
neuroendocrine markers in, 2590
neuron specific enolase in, 2590
p16 in, prognosis and, 416
radiotherapy for

complementary health practices with, 615
outcome of, prostate specific antigen and, 2305
prostate specific antigen status and, 2110
vs. radical prostatectomy, 425
vs. radical prostatectomy or watchful waiting, selection criteria for, 1122
second tumors after, 398
sexual dysfunction and, 1454
urinary dysfunction and, 1454
risk assessment for, artificial neural networks for, 2655
second tumors in, after radiotherapy vs. surgery, 398
strontium-89 for, acute myelogenous leukemia after, 620
surgery for. *See* Prostatectomy
survivors of, quality of life for, 1454
thiol-mediated apoptosis in, 2092
treatment of, practice patterns in, 1277 (editorial)
tumor markers in, UICC workshop on, 955

Prostatectomy
vs. radiotherapy, 425
vs. radiotherapy and watchful waiting, selection criteria for, 1122
sexual dysfunction and, 1454
in Sweden, 1445
urinary dysfunction and, 1454

Prostate specific antigen
outcome after radiation therapy and, 2305
in radiation-treated prostate cancer, 2110
UICC workshop on, 955

Prostate specific membrane antigen
after androgen deprivation surgery, 407
UICC workshop on, 955

Protease inhibitors, HIV-related non-Hodgkin's lymphoma outcome and, 1696

Proteomics, 2

Psychologic distress, in head and neck cancer, 2818

Psychosocial support, for cancer patients
assessment instrument for, 217
unmet needs for, 217

Pulmonary. *See also under* Lung

Pulmonary function tests, radiation-induced changes in, lung perfusion scans in prediction of, 2135

Pulmonary metastasis, in melanoma, interleukin-2 for, 2042

Q

Quality assessment, indicators for, 701

Quality of life
of Chinese cancer patients, 1715
in colorectal cancer survivors, 1294
Edmonton Symptom Assessment Scale and, 2164
in esophageal cancer, 1781
pain diary and, 2387
in prostate cancer survivors, 1454
in radiation-treated breast cancer, 2260
symptom prevalence and intensity and, 1175

Questionnaires, for palliative care needs assessment, 900

R

R₂₄ anti-Gd3 monoclonal antibody, for metastatic melanoma, 2694

Race

breast cancer survival and, 114
cancer incidence rates in, 2642
pain management and, 1929

Radiation, thyroid cancer and, exposure duration and disease extent in, in children, 1470

Radiation therapy. *See also* Chemoradiotherapy

for aggressive fibromatosis, 1517

for astrocytomas, 2350

brachytherapy

for esophageal cancer, with concurrent chemotherapy, 988

for glioblastoma multiforme, 2797

for breast cancer

with coexistent lobular carcinoma, 978, 982 (editorials), 1072

in ductal carcinoma in situ, 1643

outcome with, age-related variation in, 369

quality of life and, 2260

for cervical cancer

Cervical cancer, p27 and p53 and, 2767

with/without thermoradiotherapy, Bax and Bcl-2 and, 132

cranial

cerebral glucose metabolism after, 693

for glioma, high-dose busulfan and thiotepa after, 685

for desmoid tumors, 1517

elective ipsilateral neck, for maxillary sinus cancer, 2246

for head and neck cancer

with accelerated schedule, in elderly, 648

with/without chemotherapy, 876

late effects of, in young adult survivors, 1667

for mammographically detected ductal in situ carcinoma, local recurrence of after, 596

for osteosarcoma of flat bones, 324

postoperative hyperfractionated, for melanoma, 88

primary axillary, for breast cancer, 1633

for prostate cancer

complementary health practices with, 615

outcome of, prostate specific antigen and, 2305

prostate specific antigen status and, 2110

vs. radical prostatectomy, 425

vs. radical prostatectomy or watchful waiting, selection criteria for, 1122

second tumors after, 398

sexual dysfunction and, 1454

urinary dysfunction and, 1454

pulmonary function test changes after, lung perfusion scans in prediction of, 2135

for supratentorial primitive neuroectodermal tumors, 2189

Radical cystectomy, outcome predictors for, 2327

Radical prostatectomy

vs. radiotherapy, 425

vs. radiotherapy and watchful waiting, selection criteria for, 1122

sexual dysfunction and, 1454

in Sweden, 1445

urinary dysfunction and, 1454

Radical trachelectomy, for cervical cancer, 1877

Radiofrequency ablation, for intrahepatic tumors, 2452

Radionuclide scanning, in prediction of radiation-induced changes in pulmonary function tests, 2135

Radiosurgery

for glioblastoma multiforme, 2797

for recurrent ependymoma, 870

stereotactic, for recurrent ependymoma, 870

Raloxifene, for breast cancer, 2047

RC-3095, for breast cancer, 1384

RC-3940-II, for breast cancer, 1384

Rectosigmoid colectomy, with cytoreductive surgery, for ovarian cancer, 389

Renal cell carcinoma

granulocyte-macrophage-colony stimulating factor and interleukin-2 for, 1892

immunotherapy for, granulocyte-macrophage-colony stimulating factor in, 1317

tumor size and DNA ploidy in, prognosis and, 835

Reproduction, assisted, pediatric cancer risk and, 2846

Reproductive factors, in soft tissue sarcoma, 786

Research, population-based, in breast cancer, community involvement in, 1214

Retinoblastoma, trilateral, screening for, 965 (letter)

Retinoblastoma protein, in pulmonary neuroendocrine tumors, 550

Retinoic acid, with granulocyte-macrophage-colony stimulating factor, for renal cell carcinoma, 1317

Retroperitoneal metastasis, from extremity soft tissue sarcoma, 364

Reverse-transcriptase polymerase chain reaction, for metastatic pancreatic cancer, 1037

Risedronate, oral, for bone metastases, 6

S

Sacral chordoma, prognostic factors in, 2122

Salivary gland cancer, mucoepidermoid, H-ras mutations in, 518

Sarcoma

bone

of flat bones, 324

granulocyte-macrophage-colony stimulating factor for, morning vs. night administration of, 2033

of head and neck, in children, 2172

epithelioid, paclitaxel for, 1614

gastrointestinal, recurrent, salvage surgery for, 66

granulocytic, with t(8;21)(q22;q22), in acute myeloid leukemia, 1939

Kaposi

classic, epidemiology and risk factors of, 500

- HIV-negative, lymphoproliferative disorders and, 708 (letter)
- salivary gland, 15
- salivary glands, 15
- soft tissue
 - extremity
 - postoperative surveillance for, 777
 - staging of, 2722
 - of extremity, retroperitoneal metastasis in, 364
 - granulocyte-macrophage-colony stimulating factor
 - for, morning vs. night administration of, 2033
 - menstrual and reproductive factors in, 786
 - uterine, prognostic factors in, 1425
- Schedule of Attitudes toward Hastened Death, 2869
- Scleroderma, docetaxel and, 1078
- Screening
 - for breast cancer
 - disease outcome and, 1756 (letter), 1758 (letter)
 - intervals for, 1282
 - for cervical cancer, insurance coverage and, 2283, 2825
 - for oral cancer, community-based, cluster randomized program for, 664
 - for trilateral retinoblastoma, 965 (letter)
- Sedentary lifestyle, breast cancer and, 1248
- SELDI analysis, 2
- Sentinel node biopsy, in breast cancer
 - accuracy of in large tumors, 2540
 - with lymphoscintigraphy, 2546
 - morbidity after, vs. with axillary node dissection, 608
 - pathologic findings in, 971 (editorial), 1099
- Sepsis, in acute lymphoblastic leukemia, dexamethasone and, 1964
- Sexual dysfunction, after prostatectomy, 1454
- Single photon emission computed tomography, in prediction of radiation-induced changes in pulmonary function tests, 2135
- Sinus cancer, elective ipsilateral neck irradiation for, 2246
- Skeletal metastasis. *See* Bone metastasis
- Skin cancer. *See also* Melanoma
 - basal cell, Mohs micrographic surgery for, perineural spread after, 1605
 - basosquamous, prognostic factors in, 1365
 - melanocytic, DNA ploidy and abnormality in, 1370
 - Merkel cell, 1842
- Skin metastases, laser capture microdissection of, 749
- Slippage-related frameshift mutations, in hepatocellular carcinoma, in Japan, 1025
- Small intestine
 - 5-fluorouracil-induced injury of, in colorectal cancer, 2425 (letter)
 - MALT lymphoma of, prognosis in, 286
- Smoking, in cancer survivors, 674
- Socioeconomic factors
 - in breast cancer incidence, 1256
 - in breast cancer treatment, 933
- Soft tissue sarcoma
 - extremity
 - postoperative surveillance for, 777
 - staging of, 2722
 - of extremity, retroperitoneal metastasis in, 364
 - granulocyte-macrophage-colony stimulating factor
 - for, morning vs. night administration of, 2033
 - menstrual and reproductive factors in, 786
 - Somatostatin analogues, for carcinoid syndrome, 770
 - Soy intake, breast cancer and, 1239, 1245
 - SPECT lung perfusion scans, in prediction of radiation-induced changes in pulmonary function tests, 2135
 - Splenic rupture, in leukemia, 480
 - Squamous cell carcinoma. *See specific sites and types*
 - Squamous papilloma, of urinary tract, condylomata acuminata and, 1679
- Staging
 - bone marrow, flow cytometric, in non-Hodgkin's lymphoma, 894
 - endoscopic ultrasonographic, of esophageal cancer, treatment response prediction and, 1184 (letter)
 - of extremity soft tissue sarcoma, 2722
 - of gastric cancer
 - International Union Against Cancer/American Joint Committee on Cancer system for, 1763 (editorial), 1797
 - National Cancer Data Base report on, 921
 - of hepatoma, pathologic TNM staging for, 538
 - of melanoma
 - Breslow thickness in, 491 (editorial), 589
 - Clark levels in, 491 (editorial), 589
 - of uterine carcinosarcoma, 2783
- Stem cells, peripheral blood, negative purging of, in breast cancer, 2754
- Stem cell transplant, for breast cancer, with isolated supraclavicular nodal metastases, 790
- Stereotactic radiosurgery
 - for glioblastoma multiforme, 2797
 - for recurrent ependymoma, 870
- Stockings, for limb lymphedema, 2833
- Streptozocin, for islet cell carcinoma, 2194 (letter)
- Strontium-89, for prostate cancer, acute myelogenous leukemia after, 620
- Sturge-Weber syndrome, in Li-Fraumeni syndrome, 433
- Suicide, physician-assisted, Schedule of Attitudes toward Hastened Death for, 2869
- Sun exposure, melanoma risk and, 2704
- Supportive care
 - needs assessment for, 217
 - Schedule of Attitudes toward Hastened Death in, 2869
 - unmet needs for, 226
- Supratentorial primitive neuroectodermal tumors, treatment of, 2189
- Surface enhanced laser desorption and ionization (SELDI) analysis, 2
- Surgery. *See also* Radiosurgery and *specific sites and types*
 - cytoreductive, for recurrent epithelial ovarian cancer, 144
 - with rectosigmoid colon reconstruction, for ovarian cancer, 389

salvage, for recurrent gastrointestinal sarcoma, 66
for small cell esophageal cancer, 262

Sweden

astrocytoma in, epidemiology of, 1492 (letter)
prostate cancer incidence and treatment in, 1445
Synucleins, in breast and ovarian cancer, 2154

T

t(8;21)(q22;q22), granulocytic sarcoma and, in acute myeloid leukemia, 1939

Tamoxifen

for breast cancer
in advanced disease, 2054
outcome with, age-related variation in, 369
for melanoma, 584
for metastatic melanoma, 79

Taxanes, onycholysis and, 2367

T-cell-rich large B-cell lymphoma, in children and adolescents, 2378

Technologic advances, 2

Tegafur, for colorectal cancer, apoptosis and angiogenesis and, 1007

Tegafur-uracil (UFT), with cisplatin, for nonsmall cell lung cancer, 318

Telomerase

in colorectal cancer, metastasis and, 1304
in iodine-nonreactive esophageal lesions, malignant potential and, 1524
in precancerous hepatic nodules, 312

Telomeric instability, in meningioma, 440

Teniposide, for acute lymphoblastic leukemia, in second remission, 1166

Teratoma

ovarian cystic, ultrasonographic characterization of, 2298
thyroid, clinicopathology of, 1149

Terminal cancer, Schedule of Attitudes toward Hastened Death for, 2869

Testicular cancer

in fathers and sons, 2319
germ cell
second nongerminal cancer in, 2629
tumor markers at recurrence of, 162

Testicular leiomyosarcoma, after high-dose oral-turbinol, 2195 (letter)

Testicular lymphoma, extranodal recurrence of, 154

Testicular metastasis, in neuroblastoma, 2636

Thermodiatherapy, for cervical cancer, Bax and Bcl-2 and, 132

Thioguanine, for large cell lymphoma, in children, 166

Thiol-mediated apoptosis, in prostate cancer, 2092

Thiotepa, for gliomas, after radiotherapy, 685

13q14 deletions, in acute lymphoblastic leukemia, 1359

Thomsen-Friedenreich antigen, in colorectal cancer, prognosis and, 1536

Thrombocytopenia, in myelosuppressive therapy, FLT3-L as predictor of, 333

Thrombocytosis, transformed into leukemia, hematopoietic cell line with endothelial features from, 344

Thrombopoietin, in chronic myelogenous leukemia, 570

Thrombosis, CNS, granulocyte-macrophage-colony stimulating factor with interleukin-2 and, in renal cell carcinoma, 1892

Thymidine phosphorylase

in gastric cancer, 2220
in transitional cell bladder cancer, prognosis and, 1131

Thyroid cancer

medullary
calcitonin normalization in, prediction of, 1909
prognostic factors in, 1139
papillary, histologic grading of, 1766 (editorial), 1902
radiation-induced childhood, exposure duration and disease extent in, 1470

Thyroid teratoma, clinicopathology of, 1149

Tiludronate, oral, for bone metastases, 6

Tissue factor, in colorectal cancer, hepatic metastasis and prognosis and, 295

TNM staging system, pathologic, for hepatoma, 538

Tonsillar cancer, human papillomavirus-associated, in Hawaii, 1464

Total body nitrogen, as chemotherapy toxicity predictor, 796

TPR-MET rearrangements, in gastric cancer, 1801

Trachelectomy, radical, for cervical cancer, 1877

Transcatheter arterial chemoembolization, for hepatocellular carcinoma, 1574

prognostic index for, 50

Transplant, bone marrow, for breast cancer, with isolated supraclavicular nodal metastases, 790

Treatment. *See also specific modalities*

late effects of, in young adult survivors, 1667

palliative, needs assessment for, 900

Triple intrathecal therapy, for CNS prophylaxis, in acute lymphoblastic leukemia, 205

Tumor markers. *See also specific markers*

in hepatocellular carcinoma, 544

in neuroendocrine lung tumors, 550

in pancreatic cancer, 1037

at recurrence of germ cell tumors, 162

Turbinol, high-dose, testicular leiomyosarcoma and, 2195 (letter)

12p abnormalities, in acute lymphoblastic leukemia, prognosis and, 1945

2-D PAGE, 2

Two-dimensional Polyacrylamide gel electrophoresis, 2

U

UFT, with cisplatin, for nonsmall cell lung cancer, 318

UK Pan-1 pancreatic carcinoma cell line, 2010

Ultrasonography

in esophageal cancer, of treatment response, 1798

in esophageal cancer staging, treatment response prediction and, 1184 (letter)

of lymph node metastasis, in melanoma, 2534

- transvaginal color Doppler, of ovarian cystic teratomas, 2298
- in treatment response assessment, in esophageal cancer, 1798
- Uracil-tegafur (UFT), with cisplatin, for nonsmall cell lung cancer, 318
- Urinary bladder. *See* Bladder
- Urinary dysfunction, after prostate cancer, 1454
- Urinary tract, squamous papilloma of, condylomata acuminata and, 1679
- Urothelial cancer. *See also* Bladder cancer
 - human mismatch repair gene hMSH2 in, 2333
 - transitional cell, ifosfamide, paclitaxel and cisplatin for, 1671
 - grading of, 1663
- Urothelial papilloma, inverted, cancer risk with, predictors of, 632
- Uterine cancer. *See also* Endometrial cancer
 - altered Ig1/Ig2 expression in, 461
- Uterine carcinosarcoma, surgical staging of, 2783
- Uterine sarcoma, prognostic factors in, 1425

V

- Vaccinia virus Ankara, for human papillomavirus-related cancers, 1650
- Vaginal cancer, human papillomavirus-associated, in Hawaii, 1464
- Vaginal radical trachelectomy, for cervical cancer, 1877
- Vascular endothelial growth factor
 - in colorectal cancer
 - angiogenesis and, 1820
 - tissue factor and, 295
 - in metastatic nasopharyngeal cancer, 255
 - in pancreatic cancer, 2239
- Vinblastine, for Hodgkin's disease, 2142
 - granulocyte-macrophage-colony stimulating factor pretreatment and, 454

Vincristine

- for acute lymphoblastic leukemia, in second remission, 1166
- for gastric B-cell lymphoma, 1979
- for Hodgkin's disease, 2142
 - granulocyte-macrophage-colony stimulating factor pretreatment and, 454
- for large cell lymphoma, in children, 166

Vinorelbine

- for lung cancer, 1353
- for melanoma, 584
- for nonsmall cell lung cancer, 1045
 - in advanced disease, 557
 - in elderly, 2678
 - with paclitaxel, for breast cancer, 2732
- Vinyl chloride-related hepatocellular carcinoma, p53 mutation in, 1030

Vitamins, gastric cancer and, 737

Vitilization, in adrenocortical carcinoma, 711

Vulvar cancer

- human papillomavirus-associated, in Hawaii, 1464
- recurrent squamous cell, prognostic factors in, 1869

W

Weight, breast cancer and, 1248

World Health Organization

- pathologic classification and grading system for bladder tumors, 1509, 1513
- supratentorial astrocytic tumor classification of, 1477
- World Health Organization Classification of Tumors*, 2888
- WY 47766, oral, for bone metastases, 6

X

Xerostomia, management of, 984

Z

Zoledronate, for bone metastases, 6

Authors' Index—Volume 88

A

- Äärimala, T., 693
 Abe, M., 2000
 Abendstein, B., 1432
 Abner, A., 1072
 Abner, A. L., 982
 Abraham, E., 664
 Abraham, R., 790
 Abramov, A., 205
 Ackerman, A. B., 491
 Adamson, B., 2367
 Adelman, L., 1477
 Adelstein, D. J., 876
 Ades, T. B., 2876
 Adler, B., 2357
 Aglietta, M., 454
 Ahmed, M. M., 2010
 Aikata, H., 312
 Aikou, T., 577
 Aird, W., 2037
 Ajaikumar, B. S., 1078
 Ajani, J. A., 262
 Akbulut, H., 2033
 Akechi, T., 2817
 Akerley, W., 497
 Akiba, S., 1131, 2220
 Akiyama, S., 1131, 2220
 Akslen, L. A., 416, 1902
 Albergaria Pereira, M. A., 711
 Albertini, M., 1892
 Albitar, M., 570, 1057, 1359
 Aldape, K., 2342
 Alderson, D., 1781
 Aleksandrovic, J., 2246
 Alfaro, E. M., 1939
 Alfieri, R., 2520
 Alisauskas, R., 333
 Aljama, A., 1544
 Allal, A. S., 648
 Allard, P., 2387
 Allen, B. J., 796
 Allen, K., 2751
 Al-Mefty, O., 440
 Alpen, B., 1801
 Alvarez, M. J., 35
 Amadori, S., 454
 Ames, F. C., 1417
 Amistà, P., 169
 Amrein, P., 2037
 Ancona, E., 2520
 Andersen, M. R., 1294
 Anderson, B. O., 2561
 Anderson, D. N., 2367
 Anderson, G. R., 1814
 Anderson, K. O., 1929
 Anderson, W. F., 95
 Ando, N., 1524
 Andrea, L., 835
 Angeli, A., 2590
 Angioli, R., 381
 Ansquer, Y., 1883
 Antila, K. J., 2149
 Anton, D., 2782
 Antonescu, C. R., 2711
 Aquino, V. M., 1710
 Arase, Y., 2471
 Arencibia, J. M., 1384
 Aridome, K., 577
 Arii, S., 295, 1820
 Arima, J., 1131
 Armada, A. A., 2848
 Arndt, V., 274
 Arvieux, C., 358
 Asch, S. M., 701
 Ashikaga, T., 1099
 Aslani, A., 796
 Asmar, L., 2054
 Athale, U. H., 480
 Atkins, H., 2350
 Atkins, M. B., 1484
 Attias, D., 205
 Auer, I. A., 894
 Austrian Gynecologic Oncology
 Study Group, 139
 Averette, H., 381
 Azizi, E., 500
 Azzouz, F., 653

B

- Baba, H., 2239
 Baccala, P., 180
 Bacchini, P., 2022
 Baciuchka-Palmaro, M., 324
 Badger, C. M. A., 2832
 Baffa, R., 24
 Bajorin, D. F., 1671
 Baker, L. H., 1159
 Bakker, P. J. M., 2116
 Balasubramaniam, M., 425, 596
 Balcerzak, S. P., 1159
 Balch, C. M., 1484
 Baldus, S. E., 1536
 Ballard, D. J., 2876
 Ballin, A., 205
 Baquet, C. R., 1256
 Barchana, M., 2357
 Barger, G., 2342
 Barreras, L., 557
 Bart, R. S., 589
 Battaglia, M., 2758
 Batuello, J. T., 2105
 Baulieux, J., 358
 Baumgartner, R., 2275
 Bautista, A. P., 468
 Bayerdörffer, E., 1801
 Bear, H. D., 978
 Beaujard, A. C., 358, 2512
 Becker, M., 648
 Bedikian, A. Y., 1703
 Bedrosian, I., 2540
 Beitler, A. L., 777
 Bella, M. A., 2731
 Bellina, M., 2590
 Beltrán, J. M., 352
 Benedetti-Panici, P., 2267, 2290
 Benedict, W. F., 550
 Benjamin, R. S., 1703
 Bennett, C. L., 2876
 Bentel, G., 2135
 Bercovici, M., 984
 Berd, D., 79
 Beretta, M. D., 2731
 Berg, D., 180
 Bergh, P., 2122
 Berkel, H. J., 95
 Berruti, A., 2590
 Berthold, F., 2636
 Bertoni, F., 2022
 Beyer, J., 2629
 Beyth, Y., 755
 Bienvenu, J., 2512
 Biko, J., 1470
 Bilchik, A., 1037, 1828
 Birembaut, P. L., 1347
 Biscaglia, R., 2022
 Bittencourt, F. V., 589
 Bladé, J., 2142
 Blair, A. E., 2876
 Bland, K. I., 933
 Blanke, C. D., 1807
 Blazeby, J. M., 1781
 Bleggi-Torres, L. F., 862
 Blum, A., 2534
 Blumberg, J., 770
 Blumenthal, R. D., 333
 Bodner, S. M., 480

Boehler, P. J., 804
Boffetta, P., 500
Bokemeyer, C., 2629
Bollito, E., 2590
Bommelaer, G., 770
Bonavina, L., 2520
Bonevski, B., 217, 226
Bonham, C. A., 538
Booser, D., 2054
Borchardt, J. S., 2876
Borger, J. H., 1633
Bornstein, B., 1072
Bosch, D. A., 2796
Bosch, F., 2142
Bosseaux, B., 1347
Bostrom, B., 1945
Bostwick, D. G., 625, 844, 853, 1513, 1663, 1679, 2326
Botterweck, A. A. M., 737
Botto, B., 454
Bouché, O., 770
Bouffet, E., 685
Bowne, W. B., 2711
Boyes, A., 217, 226
Boyett, J. M., 1166
Brabbins, D. S., 425
Bracarda, S., 1438
Brachet, A., 358
Brady, H. R., 2092
Brandes, A. A., 169
Brandt, J., 2105
Brathauer, G. L., 2072
Braun, A., 2350
Braun, S., 2252
Braunschweiger, P., 381
Braverman, A. S., 2367
Brawer, M. K., 955
Bręborowicz, D., 2061
Breidert, M., 1801
Breitbart, W., 2868
Brennan, M. F., 66, 2711, 2721
Brenner, D. J., 398
Brenner, H., 274
Brescia, R., 2868
Breuer, R., 1599
Breuninger, H., 2534
Brewster, W. R., 2782
Brierre, J. E., 1353
Brodowicz, T., 1979
Brown, W. D., 1477
Browne, D., 1187, 1272
Bruening, W., 2154
Bruera, E. D., 2859
Bubalo, J. S., 637
Buccheri, G., 2677
Buchanan, G. R., 1166, 1687, 1710
Bukara, M., 468
Burcharth, F., 2487

Burgart, L. J., 154
Burger, R. A., 2782
Burhansstipanov, L., 1207
Burris, H. A., III, 1353
Burstein, D. E., 2774
Burstein, Y., 205
Burton, L., 217, 226
Buzaid, A. C., 1484, 1703
Buzdar, A. U., 1417, 2054

C

Cabahug, C., 2350
Cady, B., 1282
Cagle, P. T., 550
Cagol, M., 2520
Cai, R.-Z., 1384
Caillot, J. L., 358, 2512
Cairo, M. S., 2378
Callam, M. J., 369
Callans, L. S., 2540
Camera, A., 75
Camós, M., 2142
Camp, R. L., 108
Campagnutta, E., 389
Campo, E., 2142
Cance, W. G., 912
Cangialose, C. B., 2876
Cano, R., 557
Canto, M. I., 1788
Canto, M. T., 2642
Cantonetti, M., 454
Cantor, A., 2751
Cantuaria, G., 381
Cao, S.-M., 255
Capelli, A., 2267
Capuzzi, D., 24
Carbone, A., 389
Carbone, C. J., 1091
Carducci, M. A., 2787
Carneiro, P. C., 711
Carollo, C., 169
Carrilho, C., 862
Carter, D., 1091
Carter, W. H., Jr., 978
Carvalho, G. F., 1122, 1454
Casale, P., 835
Cascinelli, N., 1484
Casey, L. R., 1325
Casimir, L., 2848
Castle, J. T., 15
Castoldi, G. L., 454
Catalona, W. J., 1122, 1454
Catasus, L., 2290
Catus, F., 770
Cawte, T. G., 1365
Cervantes, F., 352, 2142
Cesaroni, S., 1438
Chak, A., 1788

Chan, C. L. W., 1715
Chang, C.-Y., 1057
Chang, H. R., 1643
Chang, K. J., 1325
Chang, S. S., 407
Chang, V. T., 1175, 2164
Chastagner, P., 685
Chau, G.-Y., 2464
Chaushu, G., 984
Chauvenet, A. R., 1166
Chayama, K., 2471
Che, X., 577
Chen, P., 2342
Chen, Z., 280
Cheng, L., 625, 632, 844, 853, 1513, 1663, 1679, 2326
Chetrit, A., 2845
Cheville, J. C., 625, 632, 844, 853, 1679
Chi, C.-W., 2464
Chiba, T., 1820
Childhood Brain Tumor Consortium, 1477
Chizuka, A., 2529
Choi, P. H. K., 1715
Chott, A., 1979
Chowhan, N., 2350
Choy, D. T. K., 1715
Choy, H., 1336
Chu, K. C., 2642
Chu, K. U., 1828
Chung, A. K., 425
Chung, C.-Y., 1359
Chung, Y.-H., 1986
Cividalli, G., 205
Clark, J. W., 180, 1807
Clark, O. H., 1139
Clavel, C. E., 1347
Clavell, L. A., 1964
Clayman, J., 1788
Cleeland, C. S., 1929
Cleveland, M. G., 1078
Clipp, E., 674
Clough, R., 2135
Cmelak, A. J., 1336
Cobo, F., 2142
Cocconi, G., 2731
Coffey, R. N. T., 2092
Cohen, A., 2357
Cohen, C., 2774
Cohen, F. J., 2047
Cohen, R., 2357
Coia, L. R., 988
Coit, D. G., 1484
Colella, D., 835
Coleman, R. E., 2135
Colgan, J. P., 154
Commiskey, P., 1256

Compton, C., 1739
 Compton, C. C., 2452
 Conant, E., 2540
 Conaway, M., 825
 Congiu, M., 2267
 Conlon, K. C., 66
 Connolly, J. L., 1072
 Consensus Conference Committee, 946
 Cook, P., 217, 226
 Cooksley, C., 1837
 Cooper, G. S., 1788
 Cornelisse, C. J., 2811
 Coronetta, F., 2267
 Corry, M., 1310
 Cortes, J., 570
 Cortés-Funes, H., 162
 Costantini, M., 2520
 Costantini, S., 75
 Cox, C. E., 2751
 Cranor, M. L., 186
 Crawford, E. D., 1159, 2105
 Crist, W. M., 1166
 Cronin, K., 2398
 Crump, M., 790
 Cruz, P. D., Jr., 749
 Curtis, R. E., 398
 Cushing-Haugen, K., 1393
 Cutillo, G., 2267
 Cygler, A. M., 1939
 Czerniecki, B. J., 2540

D

Dabis, F., 1696
 Dagovic, A., 2246
 Daling, J. R., 1393, 2561, 2570
 Dalton, V. K., 1964
 D'Amico, A. V., 2110
 Dammacco, F., 454
 D'Andrea, G., 2267
 Danieli, D., 169
 Da Prada, G. A., 2758
 Dargent, D., 1877, 1883
 Das, B. C., 1565
 Dash, B. C., 1565
 Datla, R. S. S., 1992
 Davenport, D. J., 1916
 Davila, E., 557
 Davis, A. M., 2721
 Davis, R., 2350
 Davis, R. L., 1477, 2342
 Daw, N. C., 2172
 Dawsey, S. M., 996
 Dawson, N. A., 825
 Daxenbichler, G., 1432
 Day, R. S., 2693
 De Angelis, V., 1438
 Debbag, R., 2848

DeLeon, C., 1929
 della Cuna, G. R., 2758
 Demark-Wahnefried, W., 674
 De Martino, M. G., 2848
 DeMatos, P., 1063
 Demeocq, F., 685
 Demidchik, E. P., 1470
 Demirkazik, A., 2033
 Denison, U., 139
 De Novellis, T., 75
 De Piero, G., 389
 Depisch, D., 2505
 Devine, P., 615
 de Vree, B. P. W., 900
 de Vries, J., 2546
 Dhom, G., 274
 Dickersin, K., 2876
 Diebold, J., 2275
 Diederichs, A., 2495
 Dienes, H. P., 1536
 Díez, M., 35
 Digue, L., 324
 Dimpfl, T., 2252
 Dinçol, D., 2033
 Diokno, A. C., 425
 Di Silverio, F., 835
 Dixon, P. F., 1728
 Dodd, P. M., 1671
 Dogliotti, L., 2590
 Dominguez, J., 50
 Dong, X. D., 1063
 Donohue, J. H., 2540
 Donovan, J., 1781
 Doolittle, N. D., 637
 Dor, J., 2845
 Dori, S., 984
 Dorval, M., 2387
 Dosaka-Akita, H., 550
 Doting, M. H. E., 2546
 Doz, F., 685
 Drach, J., 1979
 Dragosics, B., 1979
 Dralle, H., 1909
 Driscoll, D. L., 1814
 Droz, J.-P., 2629
 Drucker, L., 755
 Duce, A. M., 35
 Ducreux, M., 770
 Duffaud, F., 324
 Dufmats, M., 1445
 Duggan, P. R., 894
 Duh, Q.-Y., 1139
 Dulai, G., 2824
 Dulguerov, P., 648
 Dumas, M. C., 1317
 Dupon, M., 1696
 Duvillard, P., 1425
 Dvorchik, I., 538

E

Easton, D., 894
 Ebert, M. P. A., 1801
 Eble, J. N., 853
 Edington, H. D., 2693
 Edwards, B. K., 2398
 Edwards, M. J., 1365
 Eferl, R., 461
 Egan, K. S., 154
 Eguchi, M., 2372
 Einhorn, L., 2629
 Einhorn, L. H., 375, 1051
 Eisenberger, M. A., 2787
 Eisenkop, S. M., 144
 Ekholm, E. M. K., 2149
 Eliachar, I., 876
 Elias, A., 95
 Ellenson, L. H., 814
 Ellerhorst, J. A., 1703
 Emi, M., 1410
 Emoto, M., 2298
 Enk, A. H., 2042
 Epelbaum, R., 2357
 Erfle, V., 1650
 Ergün, S., 344
 Erland, J. B., 1353
 Ernester, V. L., 946
 Ertan, A., 524
 Eshelman, D. A., 1687
 Esteban, E., 162
 Esteve, J., 2142
 Eton, O., 1703
 Etzioni, R., 1294
 Eyre, H. J., 933

F

Fabregat, J., 50
 Fader, D. J., 1605
 Fagioli, F., 454
 Fan, D. M., 280
 Fan, M., 2135
 Fanburg-Smith, J. C., 2181
 Faoro, L. N., 862
 Farahati, J., 1470
 Farley, D. R., 2540
 Farmer, M. M., 2824
 Farndon, J. R., 1781
 Fasan, M., 563
 Fata, F., 2447
 Faure, J. L., 358
 Favre, R., 324
 Feig, B. W., 1417
 Felice, M. S., 1939
 Felsner, P., 461
 Fenoglio-Preiser, C. M., 1739
 Fernandex, M. C., 2838
 Fernandez, C., 2848
 Fernández-Aceñero, M. J., 1544

Ferrara, R., 454
 Ferreira Alves, V. A., 711
 Ferrigno, D., 2677
 Ferrozzi, F., 2731
 Fettman, M. J., 1916
 Feuerman, M., 1175, 2164
 Feun, L. G., 584
 Fiedler, W., 344
 Fielding, L. P., 1739
 Fielding, R., 1715
 Figueras, J., 50
 Filas, V., 2061
 Filippa, D. A., 186
 Finkelstein, D., 180
 Finnie, D., 524
 Fioretti, F., 786
 Firth, I., 88
 Fischer, H.-P., 2668
 Fischer, M., 461
 Fitch, T. R., 124
 Fitzpatrick, J. M., 2092
 Fleming, I. D., 1484
 Fliers, E., 2116
 Fockens, P., 2429
 Fonseca, R., 154
 Fontana, D., 2590
 Fontaumard, E., 358
 Foote, R. L., 870
 Forastiere, A., 1788
 Fornetti, P., 1438
 Fortin, D., 637
 Fossa, S. D., 2629
 Fossella, F. V., 1837
 Foster, B. M., 1687
 Fowble, B., 1403
 Fraker, D. L., 2540
 Fralix, K. D., 2010
 Franceschi, S., 389, 500, 786
 François, Y., 358, 2512
 Frazier, R. C., 596
 Frech, I., 139
 Fredholm, H., 2661
 Freeman, J. W., 2010
 Freireich, E., 1057, 1359
 Friedman, R. L., 144
 Frisch, M., 1464
 Frye, D., 2054
 Fuchs, C. S., 180
 Fujie, H., 2478
 Fujimoto, S., 2578
 Fujimoto, T., 2578
 Fujishima, M., 286
 Fujita, M., 550
 Fujitaka, T., 1007
 Fujiwara, Y., 1037
 Fukuda, T., 2239
 Fukuda, Y., 1007
 Funesti-Esch, J., 2868

Funovics, J., 2505
 Furukawa, T., 1131
 Furutani, M., 1820

G

Gabbert, H. E., 1614
 Gad, A., 2661
 Gadwal, S. R., 2181
 Gagnon, B., 2859
 Galieta, M., 2868
 Galindo-Gallego, M., 1544
 Gallego, M. S., 1939
 Gallo, A., 389
 Gallus, S., 786, 2703
 Gamito, E. J., 2105
 Ganjoo, K. N., 1051
 Gannon, F. H., 2181
 Ganz, P. A., 2824
 Garavelli, P., 563
 Garbe, C., 2534
 Garbe, L., 324
 Garbit, F., 2512
 García-Carranca, A., 1650
 García-Llano, J. L., 162
 Gardiman, M., 169
 Garipagaoglu, M., 2135
 Gaspar, L. E., 988
 Gaspar, M. J., 35
 Gastroph, S., 2252
 Gatalica, Z., 1378
 Gaudin, P. B., 407
 Gaynon, P. S., 1945
 Gazdar, A. F., 749
 Gazelle, G. S., 2452
 Gehling, U. M., 344
 Gelber, R. D., 1964
 Genestie, C., 1425
 Gentet, J.-C., 685
 Geramou, M., 139
 Gerbing, R. R., 2838
 Gerharz, C. D., 1614
 Gerl, A., 2629
 Gesme, D. H., Jr., 2876
 Ghali, G. E., 2803
 Ghiringhello, B., 1869
 Giasson, B. I., 2154
 Gibbons, N., 2092
 Gibbs, J. F., 777
 Gidel, C., 1359
 Giles, F. J., 570
 Gilles, F. H., 1477
 Gilly, F. N., 358, 2512
 Gimm, O., 1909
 Giorda, G., 389
 Girgis, A., 217, 226
 Glazer, P. M., 1091
 Glehen, O., 358, 2512
 Glick, K. M., 1964

Glusman, J., 2047
 Gobitti, C., 563
 Godwin, A. K., 2154
 Goetze, J. P., 2487
 Goldberg, S. N., 2452
 Goldbohm, R. A., 737
 Goldenberg, D. M., 333
 Goldstein, N. S., 596, 2228, 2553
 Gollard, R., 1842
 Golledge, J., 369
 Gomes, G. C., 711
 Gonzales, A., 1828
 Gonzalez, J. A., 425
 Goodman, M. T., 1464
 Googe, J. D., 2803
 Gorman, D. A., 870
 Gornbein, J. A., 1643
 Goss, P. E., 790
 Gradishar, W., 2047
 Graf, A. H., 139
 Graham, M., 988
 Graham, V. V., 1650
 Grandclément, E., 2512
 Granell, J., 35
 Granger, G. A., 1325
 Grant, C. S., 2540
 Grau, C., 1852
 Grauer, L. S., 407
 Greco, F. A., 1353
 Greenway, H. T., 1842
 Grenon, N., 180
 Greul, R., 2505
 Grimes, M. M., 978
 Grol, R. P. T. M., 900
 Groome, P. A., 1728
 Groot, K., 1384
 Gross, K. L., 1916
 Grossbard, M. L., 180
 Group d'Epidémiologie Clinique du
 SIDA en Aquitaine (GECSA), 1696
 Guardiola, J., 50
 Gücer, F., 139
 Guglielmi, B., 169
 Gumbs, A. A., 1091
 Gundersen, S., 804
 Gunterberg, B., 2122
 Günzel, S., 1370
 Guo, X., 255
 Gupta, R. C., 1565
 Guthrie, J., 1224
 Gutman, M., 364

H

Habermann, T. M., 154
 Haffty, B. G., 1091
 Haga, S., 1410
 Haidar, M., 1359
 Haidar, M. A., 1057

Haider, K., 2505
 Haie-Meder, C., 1425
 Haim, N., 2357
 Hainsworth, J. D., 1353
 Halabi, S., 825
 Hall, E. J., 398
 Hall, S. F., 1728
 Hall, W. A., 637
 Halmos, G., 1384
 Halvorsen, O. J., 416
 Hamaki, T., 2529
 Hamamura, K., 1557
 Han, S., 1623, 2319
 Hand, M. S., 1916
 Hanisch, F.-G., 1536
 Hank, J. A., 1892
 Hanlon, A., 1403
 Hannisdal, E., 804
 Hansen, R. A., 1916
 Hanson, E. J., 637
 Hara, K., 2210
 Hara, T., 2372
 Hareyama, H., 2578
 Harila-Saari, A., 693
 Harima, K., 132
 Harima, Y., 132
 Harlow, S. P., 1099
 Harris, J. R., 1072
 Hart, A. A. M., 1633
 Hartmann, J. T., 2629
 Hartmann, L. C., 124
 Hartmann, O., 685
 Hasuike, Y., 1549
 Hatfield, A. K., 124
 Hattori, H., 2372
 Hauck, W. W., 24
 Haukaas, S., 416
 Hawkins, W. G., 2711
 Hayashi, H., 268
 Hayashi, N., 544
 Haydon, M. S., 2803
 Haynes, M. A., 1189
 He, J., 1230
 Healey, J. H., 2721
 Heath, E., 1788
 Hedley-Whyte, T. E., 1477
 Heelan, R. T., 1045
 Heerema, N. A., 1945
 Heffernan, M., 1082
 Heffess, C. S., 1149
 Hegarty, N. J., 2092
 Heikens, J., 2116
 Heilman, D. K., 1051
 Heine, M., 1370
 Hejna, M., 1979
 Heller, R., 2540
 Henderson, I. C., 2876
 Henke, R. P., 344

Hentschel, P., 2350
 Hepp, F., 2252
 Hermanek, P., 1763
 Hernández, P., 35
 Hernández Nieto, L., 352
 Hero, B., 2636
 Heron, D. E., 2739
 Herr, H., 1671
 Herrera, L., 1710
 Herskovic, A., 988
 Heston, W. D. W., 407
 Hetelekidis, S., 1072
 Hiatt, R. A., 2283
 Hibberts, J. L., 1703
 Hibi, S., 1970
 Higgins, G., 1671
 Hillemanns, P., 2275
 Hillman, D. W., 124
 Hilton, S., 1671
 Hinze, R., 1909
 Hirai, H., 2529
 Hirohashi, K., 1016
 Hiroumi, H., 550
 Hisanaga, Y., 58
 Hiyama, E., 1955
 Hiyama, K., 1955
 Hoebbers, F. J. P., 1633
 Hoff, P. M., 2054
 Hoffman, J., 1403
 Hoffmann, J., 1801
 Hoisæter, P. Å., 416
 Hokita, S., 577
 Hollis, D., 2135
 Holowaty, E. J., 1728
 Hölscher, A. H., 1536
 Holt, S. K., 2561
 Hon, J. K., 1353
 Hong, M.-H., 255
 Hong, W. K., 1837
 Hoon, D. S. B., 1037
 Horibe, K., 1970
 Horie, Y., 529
 Horiuchi, S., 2298
 Hortobagyi, G. N., 1082, 2054
 Horwich, A., 2629
 Hossfeld, D. K., 344
 Host, H., 804
 Høstmark, J., 416
 Hotton, K. M., 1892
 Houghton, A., Jr., 1484
 Howe, H. L., 2398
 Hsieh, J.-T., 2333
 Huang, C.-L., 2464
 Huang, Z., 761
 Huebner, K., 24
 Huikuri, H. V., 2149
 Hukutomi, A., 2210
 Hulshof, M. C. C. M., 2796

Humberson, C., 1842
 Hundahl, S. A., 921
 Hunt, J. D., 468
 Hunt, K. K., 1417
 Hunter, C. P., 1193
 Hurley, J., 584, 1929
 Hurwitz, C. A., 1964
 Husain, M., 440
 Hussain, S., 2367
 Hutchinson, B., 407
 Hutchinson, R., 1945
 Hutter, R. V. P., 2653
 Hwang, S. S., 1175, 2164
 Hyslop, T., 2739

I

İçli, F., 2033
 Icasiano, E., 1671
 Ichinose, Y., 318
 Ide, T., 312
 Ihara, K., 2372
 Iida, M., 286
 Iizuka, S., 1970
 Ikawa, S., 529
 Ikebe, T., 1016
 Ikeda, K., 2471
 Ikenoue, T., 1530
 Ikuta, K., 1970
 Iliya, A., 2350
 Imamura, M., 295, 1557, 1820
 Imashuku, S., 1970
 Imazono, Y., 1131
 Imberti, G. L., 2703
 Ingle, J. N., 124, 1265
 Inoue, A., 1304
 Inoue, H., 1574
 Intrator, O., 1599
 Inwards, D. J., 154
 Iscovich, J., 500
 Isenberg, G., 1788
 Ishigami, S., 295, 577
 Ishii, E., 2372
 Ishikawa, H., 2210
 Isigami, S.-I., 1820
 Itabashi, M., 996
 Italian Cooperative Group on AIDS
 and Tumors, 563
 Ito, H., 1007
 Ito, N., 1025
 Ituarte, P. H. G., 1139
 Iwasaki, A., 1304
 Iwashige, H., 577
 Iwashita, A., 996
 Iwatsuki, S., 538

J

Jackson, J. S. H., 1852
 Jacob, B. J., 664

Jalonen, J., 2149
Janni, W., 2252
Jansen, J. C., 2811
Jansen, L., 2546
Janss, A. J., 2189
Janssen-Heijnen, M. L. G., 2598
Janssens, A. M., 1769
Japan UFT Lung Cancer Study Group, 318
Jass, J. R., 969
Jaszczak, R., 2135
Jaurieta, E., 50
Jekunen, A. P., 1863
Jenkins, J. J., 198, 2172
Jeremic, B., 2246
Jiang, D., 761
John, W., 1807
Johnson, D. H., 1336
Johnson, F. E., 777
Johnson, J. L., 1063
Johnson, T. M., 1605
Johnson-Thompson, M. C., 1224
Jonasdottir, T. J., 1393
José, M. V., 1650
Joslyn, S. A., 114
Juillard, G. J. F., 1643
Julian, J., 2260
Juweid, M., 333

K

Kaban, K., 570
Kahán, Z., 1384
Kähkönen, M., 693
Kahlenberg, M. S., 1814
Kahn, K., 2824
Kaider, A., 139
Kaido, T., 295
Kaim, M., 2868
Kainz, C., 139
Kajiwar, T., 1410
Kajiyama, G., 312
Kakkar, R., 1992
Kaleva-Kerola, J., 1863
Kalifa, C., 685
Kalir, T., 2774
Kamada, N., 2010
Kami, M., 2529
Kaminishi, M., 2443
Kamura, T., 2584
Kanamori, S., 2210
Kanda, Y., 2529
Kanetsuki, I., 1574
Kantarjian, H., 570, 1057, 1359
Kanz, L., 2629
Kao, G. D., 615
Kapshammer, E., 139
Karczewska, A., 2061
Kardinal, C. G., 124

Karsten, U., 1536
Kasimis, B. S., 1175
Kaste, S. C., 198, 480, 2172
Kastelein, J. J. P., 2116
Kasumi, F., 1410
Katai, H., 1796
Katiyar, S., 1565
Kato, H., 1285
Kato, Y., 996
Katopodis, N., 1828
Katz, S. C., 2711
Kaur, J. S., 1203
Kawabe, T., 1530
Kawaguchi, R., 1530
Kawakami, Y., 312, 550
Kawarabayashi, T., 2298
Kawasaki, H., 529
Kawata, S., 1025
Kearney, K. A., 2283
Keating, M., 1057, 1359
Kebebew, E., 1139
Kelley, M., 1037
Kelly, W. K., 1671
Kemeny, N., 2447
Kemp, B. L., 1837
Kendall, B., 814
Kenner, L., 461
Kentenich, C., 2252
Kerr, E. A., 701
Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services, 2876
Kesler, K. A., 1051
Kestin, L. L., 425, 596, 2305, 2553
Khorsand, M., 1892
Khuri, F. R., 1837
Kigawa, J., 2584
Kikkawa, N., 1549
Kikuchi, Y., 2584
Kilic, N., 344
Kim, B. K., 749
Kim, H.-J., 1623
Kim, H.-Y., 1623
Kim, I.-K., 2082
Kim, J. W., 2082
Kim, K. M., 1892
Kim, K. S., 2082
Kim, S. R., 1623
Kim, Y.-D., 1623
Kimura, S., 2478
Kindblom, L.-G., 2122
King, K.-L., 2464
Kinney, W., 2283
Kinoshita, H., 1016
Kinukawa, N., 2438
Kiriya, S., 58
Kirkbride, P., 2260

Kirkwood, J. M., 1484, 2693
Kirschner, M. A., 711
Kiso, S., 1025
Kita, T., 2584
Kitagawa, Y., 1524
Kitajima, M., 1524
Kitamoto, M., 312
Kitayama, J., 42
Klausner, J. M., 364
Kleihues, P., 2887
Klein-Szanto, A. J. P., 2154
Klimstra, D., 2447
Klöppel, G., 2495
Knight, R. D., 1082
Knop, J., 2042
Knopf, C., 1614
Ko, Y., 2668
Kobayashi, M., 2471
Kocha, W. L., 988
Köckerling, F., 1030
Koda, M., 529
Koedooder, C., 2796
Koenig, K., 589
Koh, M. S., 1986
Kohler, M. F., 2782
Koike, K., 2478
Koike, M., 996
Kolls, J. K., 468
Komarnicky, L. T., 2739
Kondo, Y., 1820
Koops, H. S., 2546
Koot, R. W., 2796
Kopans, D. B., 1282
Kopf, A. W., 589
Korhonen, T., 693
Kornek, G., 1979
Kornek, G. V., 2505
Kossman, S. E., 620
Kosty, M. P., 1842
Kovatch, A. J., 24
Koyanagi, K., 1524
Kraemer, D. F., 637
Krag, D. N., 1099
Krailo, M. D., 2838
Krauss, G., 2505
Kraybill, W. G., 777
Kremer, B., 2495
Krill, E., 557
Kris, M. G., 1045
Krisht, A., 440
Kronenberg, J., 984
Krook, J. E., 124
Kroon, B. B. R., 2546
Krug, L. M., 1045
Krygiel, J., 1454
Kuba, M., 318
Kubo, S., 1016
Kudoh, S., 318

Kugaya, A., 2817
 Kuiper, A., 2811
 Kumada, H., 2471
 Kumada, T., 58
 Kumar, N. B., 2751
 Kun, L. E., 2172
 Kunze, D., 1536
 Kuo, C., 1037
 Kurahara, K., 286
 Kurosaki, T. T., 1325
 Kusano, M., 1285
 Kuzel, T., 1317
 Kwasny, W., 2505

L

Labbé, J., 2387
 Labouyrie, E., 1696
 Lacerna, M. D., 596
 Lahousen, M., 461
 Lai, S., 584
 Laitinen, K. L. J., 1590
 Lake, D., 825
 Lange, B. J., 1945
 Lanza, A., 2758
 Larson, M., 1892
 Larto, M. A., 876
 Latronico, A. C., 711
 Lau, W. H., 1715
 Laughner, E., 2606
 La Vecchia, C., 786, 2703
 Lavertu, P., 876
 Lawlor, P. G., 2859
 Lawton, T., 2540
 Lax, S. F., 814
 Leach, F. S., 2333
 Lebesque, J. V., 1633
 Leblanc, E., 1883
 Lee, A. W. M., 1715
 Lee, C. G., 2082
 Lee, G. C., 1986
 Lee, J. M., 2082
 Lee, J. S., 1837
 Lee, M., 2342
 Lee, M. K., 1945
 Lee, M.-S., 1623
 Lee, V. M.-Y., 2154
 Lee, Y. S., 1986
 Legha, S. S., 1703
 Lehnert, G., 1030
 Lei, D., 468
 Leibovich, B. C., 844, 1679, 2326
 Lele, S. M., 1378
 Lenert, J. T., 1417
 Leppers vd Straat, F. G. J., 884
 Lerman, R. H., 2199
 Lerner-Geva, L., 2845
 Leung, D. H. Y., 2711
 Leung, E. C., 1325

Lev-Chelouche, D., 364
 Levi, J. A., 796
 Levine, M., 2260
 Levis, A., 454
 Levitan, N., 1788
 Leviton, A., 1477
 Lew, D., 1159
 Lew, W., 333
 Lewin, K. J., 996
 Lewis, J. J., 66, 2711
 Lewis, M., 557
 Lhommé, C., 1425
 Li, A. F.-Y., 2464
 Li, B. D. L., 2803
 Li, C. I., 2561, 2570
 Lianes, P., 162
 Liao, S.-Y., 1108
 Liberman, B., 711
 Liberman, L., 971
 Liebmman, P. M., 461
 Lilenbaum, R., 557
 Lin, Y.-W., 1970
 Lindforss, U., 2661
 Lipkus, I., 674
 Lipton, A., 1082
 Litchy, S., 1353
 Liu, N. S., 1837
 LiVolsi, V. A., 1902
 Lladó, L., 50
 Loehrer, P. J., 1807
 Loesch, D., 375
 Lohse, C. M., 632
 Lones, M. A., 2378
 López-Guillermo, A., 2142
 López-López, J. J., 162
 Lossos, A., 1599
 Lossos, I. S., 1599
 Lowe, L., 1605
 Lu, J., 761
 Lu, Y., 2047
 Lucania, A., 75
 Lui, W.-Y., 2464
 Luider, J., 894
 Lüttges, J., 2495
 Lutz, P., 685
 Lutzky, J., 557
 Lynch, H. T., 433
 Lynch, J., 2105
 Lynch, J. F., 433
 Lynch, T. J., 180
 Lythcott, N., 1214

M

Maarouf, M., 2796
 Macchia, V., 75
 Machens, A., 1909
 Machin, P., 2290
 Mackiewicz, A., 2061
 Mackillop, W. J., 1728
 MacNeill, K., 2037
 Madajewicz, S., 2350
 Maeda, M., 2210
 Maeda, S., 1530
 Mafune, K., 1530
 Magalhaes, A., 381
 Mahmoud, H. H., 2172
 Mai, W.-Y., 255
 Maiche, A. G., 1863
 Mailliard, J. A., 124
 Maire, D., 648
 Makuuchi, M., 2478
 Malek, R. S., 1679
 Malfertheiner, P., 1801
 Malin, J. L., 701, 2824
 Malkowicz, S. B., 2110
 Mallinckrodt, C. H., 1916
 Malone, K. E., 1393
 Maluf, F., 2447
 Mambri, A., 2731
 Man, Y.-G., 2072
 Mancini, I. L., 2859
 Mandel, M., 2845
 Maneschi, F., 2267
 Mangeonjean, C. C., 1347
 Mansfield, C. M., 2739
 Manshouri, T., 1057, 1359
 Manzione, J., 2350
 Marghoob, A. A., 589
 Mari, M., 2590
 Mariano, A., 75
 Marimoutou, C., 1696
 Marini, A., 584
 Marks, L. B., 2135
 Marsh, J. W., 538
 Martenson, J. A., 154
 Marth, C., 1432
 Martin, R. C. G., II, 1365
 Martin, X., 1877
 Martinez, A. A., 425, 596, 2305
 Maruyama, K., 1796
 Mascari, R. A., 2693
 Massullo, V., 1842
 Mastrangelo, M. J., 79
 Mates, D., 1852
 Mathevet, P., 1877
 Mathew, B., 664
 Matias-Guiu, X., 2290
 Matsuda, A., 2220
 Matsuda, Y., 1025
 Matsumoto, T., 286
 Matsushita, S., 2220
 Matsuura, T., 1007
 Matsuura, Y., 1955
 Matsuyama, T., 2529
 Matsuzaki, A., 2372
 Matsuzawa, Y., 1025

Matthay, K. K., 2838
 Mattila, J., 1590
 Mattingly, C., 2010
 Maunsell, E., 2387
 Maybee, D. A., 1166
 Mayer, R. J., 180
 Mazumdar, M., 1671
 McAllister, L. D., 637
 McBride, C., 674
 McCaffrey, J. A., 1671
 McCarthy, W. H., 88
 McComb, R. D., 433
 McConnell, J. D., 2333
 McCue, P. A., 24
 McGinnis, L. S., 933
 McGinnis, L. S., Jr., 2876
 McGlynn, E. A., 701
 McGrath, P. C., 2010
 McLeod, D. G., 2105
 McManus, M., 2367
 McMasters, K. M., 1365
 McNeese, M. D., 2054
 McTiernan, A., 1248
 Mearini, E., 1438
 Medgyesy, D. C., 262
 Medonca, B. B., 711
 Meek, A., 2350
 Meis-Kindblom, J. M., 2122
 Mellars, K., 1082
 Menck, H. R., 912, 921, 933
 Mendez, L., 381
 Mendoza, N. M., 1650
 Mendoza, T. R., 1929
 Meng, X., 761
 Menke, M. A. O. H., 2495
 Merchant, H., 1650
 Merchant, T. E., 198
 Merigliano, S., 2520
 Merimsky, O., 364
 Metsähonkala, L., 693
 Meyer, W. H., 2172
 Michaelson, J. S., 1282
 Micheletti, L., 1869
 Mick, R., 2540
 Miehke, S., 1801
 Mihm, M. F., 1484
 Miike, R., 2342
 Mikami, I., 2817
 Milchgrub, S., 749
 Milicic, B., 2246
 Miller, D. S., 2398
 Miller, G. J., 1159
 Miller, K. D., 375
 Miller, M., 2283
 Miller, V. A., 1045
 Min, H. K., 2082
 Min, H.-Q., 255
 Miner, M. E., 637

Minn, H., 693
 Mirhashemi, R., 381
 Mirza, N. Q., 1417
 Mitsuda, A., 529
 Mitsushima, T., 1530
 Miwa, A., 2529
 Miyakawa, T., 2298
 Miyashiro, M., 1037
 Miyazono, N., 1574
 Modan, B., 2845
 Moe, R. E., 2561
 Mohiuddin, M., 2010
 Mohr, P. J., 1336
 Moinfar, F., 2072
 Moinpour, C., 1294
 Molberg, K., 2333
 Monden, M., 1037
 Monfardini, S., 169
 Mönig, S. P., 1536
 Monk, B. J., 2782
 Monteau, M., 1347
 Montemurro, F., 454
 Montie, J., 2105
 Montie, J. E., 2655
 Montoto, S., 2142
 Montserrat, E., 352, 2142
 Mooney, K., 2876
 Mora, J., 162, 186
 Mori, A., 1820
 Mori, K., 1530
 Mori, T., 1970
 Morice, P., 1425
 Morisaki, T., 2438
 Moriya, K., 2478
 Morlat, P., 1696
 Morrow, M., 933
 Mortenson, L. E., 2876
 Mortimer, P. S., 2832
 Morton, D. L., 1484, 1828
 Mosca, A., 2590
 Mudan, S. S., 66
 Mueller, P. R., 2452
 Múguenza, J. M., 35
 Mukai, M., 1524
 Muldoon, L. L., 637
 Müller-Holzner, E., 1432
 Munley, M., 2135
 Munshi, N., 375
 Murakami, T., 302
 Murashima, N., 2471
 Murata, F., 245
 Murawaki, Y., 529
 Murphy, G. P., 955
 Muto, T., 42

N

Nachman, J. B., 1945
 Nagata, K., 132

Nagawa, H., 42
 Nagy, T., 790
 Nair, S., 124
 Najeeb, K., 664
 Nakache, R., 364
 Nakajo, A., 577
 Nakajo, M., 1574
 Nakamori, S., 1037
 Nakamura, K., 2201, 2438
 Nakamura, S., 286
 Nakamura, Y., 312, 1410
 Nakanishi, T., 312, 544
 Nakanishi, Y., 1285
 Nakano, M., 544
 Nakano, S., 58
 Nakano, T., 2766, 2817
 Nakata, Y., 1970
 Naldi, L., 2703
 Namkoong, S. E., 2082
 Narducci, F., 1883
 Nariko, H., 2443
 Naruke, M., 2686
 Nascimento, A. G., 844
 Nashan, D., 2042
 Nathan, F. E., 79
 Natsugoe, S., 577
 Nawrocki, B., 1347
 Nawrocki, S., 2061
 Neal, C., 1393
 Negri, E., 786
 Nehra, A., 1663, 1679, 2326
 Nikolaichuk, C., 2859
 Nelson, C. J., 2868
 Nelson, D. F., 870
 Nelson, S., 468
 Nemori, R., 2201
 Nemoto, T., 2201
 Nesland, J. M., 804
 Neuberg, D., 2037
 Neumann, A., 755
 Neumann, R. M., 625, 844, 1663, 2326
 Neunteufel, W., 139
 Neuwelt, E. A., 637
 Ng, K. K., 1045
 Nguyen, P. T., 1325
 Nichols, C. R., 2629
 Nielsen, F. C., 2487
 Nieweg, O. E., 2546
 Niitani, H., 318
 Nikolic, N., 2246
 Nioh, T., 2220
 Nishida, H., 1574
 Nishiguchi, S., 1016
 Nishimata, H., 2220
 Nishimata, Y., 2220
 Nishimoto, K., 1828
 Nishimura, S., 1955

Nishisaka, T., 1007
 Nishiyama, K., 1131
 Nitanda, T., 2220
 Nitta, T., 245
 Nixon, A., 1072
 Nixon, R., 637
 Nolden, S., 1536
 Nomdedeu, B., 2142
 Nordenskjöld, K., 1445
 Norris, B. A., 1378
 Norvasuo-Heilä, M.-K., 693
 Noshiro, H., 2438
 Nuyttens, J. J., 1517

O

O, S. K., 1715
 Obama, H., 2298
 Obermair, A., 139
 Obertop, H., 2429
 Obi, S., 1557
 O'Brien, C., 1393
 O'Brien, C. J., 88
 O'Brien, S., 570, 1057
 Ochiai, A., 1285
 O'Connell, M., 1099
 Oeffinger, K. C., 1687
 Offerhaus, G. J. A., 2429
 Offner, F. C., 1769
 Oga, A., 268
 Ogata, N., 302
 Ogawa, M., 2000
 Ogilvie, G. K., 1916
 Ogle, K. S., 653
 Ogura, K., 1530
 Ohashi, K., 2201
 Ohashi, S., 2210
 Oh, Y., 1131
 Ohnishi, T., 132
 Ohyama, K., 529
 Ohzato, H., 1549
 Oka, A., 132
 Oka, K., 2766
 Oka, M., 268
 Okamoto, K., 2578
 Okamura, H., 2817
 Okamura, S., 2210
 Okuda, H., 544
 Okuyama, T., 2817
 Olivecrona, H., 2661
 Olivotto, I. A., 946, 1852
 Olmos, R. A. V., 2546
 Omata, M., 1530, 1557
 Oncology Cooperative Group of the
 Italian Group for Epidemiologic
 Research in Dermatology
 (GISED), 2703
 O'Neill, A., 2092
 O'Neill, B. P., 154

Onodera, H., 295, 1820
 Ontario Clinical Oncology Group,
 2260
 Onur, H., 2033
 Oosterhuis, J. W. A., 2598
 Orel, S. G., 2540
 Ortiz-Pallardó, M. E., 2668
 Osada, T., 42
 Osborn, N. K., 433
 Osse, B. H. P., 900
 Ostapenko, V. V., 132
 Österreichischer, C., 1979
 Ostrander, E. A., 1393
 Osuch, J. R., 1230
 O'Sullivan, B., 1728
 Osztie, E., 637
 O'Toole, D., 770
 Oyasu, R., 1509
 Ozawa, S., 1524

P

Pääkkö, P., 1590
 Packer, R. J., 2189
 Padmore, R. F., 1403
 Paganini, H. R., 2848
 Palos, G., 1929
 Paltiel, O., 2357
 Pamir, A., 2033
 Pan, B. R., 280
 Pandey, M., 664
 Paner, G. P., 1582
 Pankratz, V. S., 632
 Panteix, G., 2512
 Papadogiannakis, N., 2661
 Papadopoulos, N. E., 1703
 Pappo, A. S., 198
 Parazzini, F., 2703
 Parenti, A., 2520
 Park, K., 1623
 Park, Y. G., 2082
 Parker, R. G., 1643
 Partin, A. W., 955, 2105, 2787
 Patchefsky, A. S., 1403
 Pathak, D. R., 1230
 Pautier, P., 1425
 Pauwels, R. P. E., 2598
 Pavlakis, N., 796
 Payne, R., 1929
 Paz-Ares, L., 162
 Peacock, J. L., 2832
 Peacock, S., 1294
 Pedrazzoli, P., 2758
 Peix, J. L., 358
 Pellegrin, J.-L., 1696
 Penalver, M., 381
 Peracchia, A., 2520
 Pereira, J. L., 2859
 Perez, E. A., 124

Perez, W., 1045
 Perkins, S. L., 2378
 Perles-Daniel, C., 324
 Perotti, C., 2758
 Peschel, R. E., 2319
 Pessin, H., 2868
 Peterse, J. L., 1633, 2546
 Peterson, B., 674
 Petrelli, N. J., 1814
 Pettigrew, N., 1739
 Pettinga, J., 596
 Pezzullo, L., 75
 Phillips, J. L., 921
 Phillips, P. C., 2189
 Picus, J., 1807
 Pierce, S., 570
 Piers, D. A., 2546
 Pilch, H., 1370
 Pinkel, D., 1166
 Pinna, G., 169
 Pisani, P., 664
 Pizzo, B., 1045
 Poitevin, G., 1347
 Pollán, M., 35
 Polliack, A., 2357
 Pollock, B. E., 870
 Pollock, B. H., 1166
 Polyak, T., 186
 Ponchio, L., 2758
 Pont, J., 2629
 Poquette, C. A., 198, 2172
 Porcheron, J., 358
 Porena, M., 1438
 Porter, P., 2561
 Potosky, A., 1294
 Poulson, J., 2135
 Prat, J., 2290
 Pratt, C. B., 198, 2172
 Pravdenkova, S., 440
 Pressman, P. I., 946
 Preti, M., 1869
 Putaud, I. C., 1347
 Putnam, J. B., Jr., 262

Q

Qian, C.-N., 255
 Quarta, M., 2731
 Querleu, D., 1883
 Quinn, M. J., 88

R

Rabitti, C., 2267
 Rabkin, M. S., 2693
 Racanelli, V., 454
 Rachmilevitz, E. A., 2357
 Raderer, M., 1979, 2505
 Radhi, J. M., 1992
 Rafecas, A., 50

Rafel, M., 352
Ragaz, J., 1852
Ragnaud, J.-M., 1696
Rajala, R. V. S., 1992
Ramadas, K., 664
Ramnani, D. M., 844, 1679, 2326
Rampy, A. B., 1378
Ramsey, K., 198
Ramsey, S. D., 1294
Rantanen, V. T., 2149
Rao, B. N., 198, 2172
Raquin, M., 685
Rassner, G., 2534
Ratia, T., 35
Ratner, D., 1605
Ratschek, M., 2072
Ravindranath, M. H., 1828
Rayón, C., 352
Rebner, M., 596
Rechavi, G., 205, 2845
Recht, A., 1072
Reddy, A. T., 2189
Reed, W., 804
Reese, D. M., 1310
Reeves, J. E., 95
Reganti, R., 1078
Rehfeld, J. F., 2487
Reinecke, P., 1614
Reiners, C., 1470
Reintgen, D., 1484
Reis-Filho, J. S., 862
Reitsma, D. J., 1082
Remotti, F., 2122
Ren, J., 280
Reuter, V. E., 407
Rey, A., 1425
Reyes, C. V., 1582
Reynolds, C., 2540
Ribeiro, R. C., 480
Richardson, K. L., 1916
Richman, S. P., 1929
Riddell, R. H., 996
Rideout, J., 2824
Ridolfo, A. L., 563
Rieger, K. M., 1051
Rieger, R., 608
Riehle, D., 632
Ries, L. A. G., 2398
Rimm, D. L., 108
Rimm, E. B., 108
Rivera, G. K., 1166
Rivoire, M., 358
Rjosk, D., 2252
Robert, E. G., 468
Robinson, R. A., 518
Rocco, S., 75
Roche, B., 1425
Roche, P., 2350

Rodary, C., 685
Rodriguez-Bigas, M. A., 1814
Rodriguez-Brieschcke, M. T. M., 2848
Rodriguez-Galindo, C., 198
Rogers, Q., 1916
Romilly-Harper, A. P., 1187, 1272
Ron, E., 398
Ron, I. G., 2447
Ronco, G., 1869
Roque, C., 2350
Rorke, L. B., 1477
Rosai, J., 1149
Rosales, R., 1650
Rosato, F. E., 24
Rosenberg, H. M., 2398
Rosenfeld, B., 2868
Rosi, P., 1438
Ross, M. I., 1417, 1484
Rosser, C., 1403
Rossi, J. G., 1939
Rosso, D. A., 1939
Rothwell, D., 1728
Rotoli, B., 75
Rowinsky, E. K., 1807
Rübben, A., 2042
Ruiz, A., 35
Ruol, A., 2520
Ruotsalainen, U., 693
Russell, C., 1929
Rust, P. F., 1517
Ruszniewski, P., 770
Rutgers, E. J. Th., 2546
Rutherford, C., 749
Ryan, C. W., 1317
Ryan, D. P., 180
Ryd, W., 2122

S

Sabo, E., 2774
Saboorian, M. H., 2333
Sacchetoni, A., 1877
Sackmann-Muriel, F., 1939
Sadeghi, B., 358
Saeki, A., 1025
Sagalowsky, A. I., 2333
Saito, A., 544
Saito, S., 42
Saitoh, S., 2471
Sakamoto, G., 1410
Sakatani, T., 1007
Sako, M., 1970
Sakuragi, N., 2578
Salamat, M. S., 1892
Salazar, R., 162
Sallan, S. E., 1964
Salmi, T. A., 2149
Salmi, T. T., 693

Salminen, E. K., 2149
Salvaneschi, L., 2758
Salvatti, M. E., 2367
Samur, M., 2033
Sandblom, G., 1445
Sandler, E. S., 1710
Sandri, S., 563
Sankaranarayanan, R., 664
Sano, T., 1796
Sanson-Fisher, R., 217, 226
Santin, A. D., 175
Santoro, E., 24
Sanz, J., 1544
Sarid, R., 500
Sarin, S. K., 1565
Sarkis, C. M., 2848
Sasaki, K., 268
Sasako, M., 1796
Sather, H. N., 1945
Sato, I., 2584
Sato, S., 1557
Sato, T., 79
Savaraj, N., 584
Sawaya, G. F., 2283
Sawyer, J. R., 440
Saxton, J. P., 876
Scalzitti, J. M., 2606
Scambia, G., 2290
Scarabelli, C., 389
Schadé, E., 900
Schäffer, U., 1370
Schally, A. V., 1384
Schapers, R. F. M., 2598
Schauenstein, E., 461
Schauenstein, K., 461
Scheithauer, W., 1979, 2505
Scher, H. I., 1671, 2787
Scherer, B. G., 2326
Schiller, J. H., 1892
Schindlbeck, C., 2252
Schlagenhauff, B., 2534
Schlemper, R. J., 996
Schmit, T., 2357
Schmitt, F. C., 862
Schmitz, M., 1614
Schneeweiss, B., 2505
Schneider, E. M., 1614
Schneider, K., 1454
Schneider, P. M., 1536
Schneyer, U., 1909
Schnitt, S. J., 1072
Schomberg, P. J., 870
Schorin, M. A., 1964
Schrenk, P., 608
Schulman, L. N., 1807
Schultz, D., 2110
Schumacher, U., 344
Schwartz, G. F., 946, 2739

Schwartz, M., 557
 Schwartz, M. R., 524
 Sciarra, A., 835
 Scott-Conner, C. E. H., 933
 Seaman, J. J., 1082
 Sebo, T. J., 632, 844, 853, 1679
 Seccareccia, F., 835
 Secic, M., 876
 Segawa, K., 2210
 Seiden, M. V., 180
 Seigler, H. F., 1063
 Semenza, G. L., 2606
 Şencan, O., 2033
 Şenler, F. Ç., 2033
 Sensel, M. G., 1945
 Seo, Y., 2239
 Sequeiros, G. B., 1863
 Serraino, D., 563
 Seto, S., 295
 Seto, Y., 2443
 Sewell, C. L., 1365
 Shachar, M. B., 2357
 Shady, M., 2350
 Shafizadeh, S. T., 1536
 Sham, J. S. T., 1715
 Shamiyeh, A., 608
 Shapira, J., 755
 Sharma, A., 550
 Sharma, M., 1051
 Sharma, R. K., 1992
 Sharon, R., 205
 Shellito, J. E., 468
 Sherman, D. E., 2774
 Shibamoto, Y., 2246
 Shibata, T., 302
 Shibata, Y., 42
 Shiina, S., 1557
 Shikata, N., 132
 Shimamoto, F., 312
 Shimaoka, S., 2220
 Shimoda, T., 996, 1285
 Shinagawa, S. M., 1217
 Shintani, Y., 2478
 Shipe-Spotloe, J. M., 2693
 Shirahama, T., 1131
 Shirai, K., 2210
 Shiratori, Y., 1530, 1557
 Shoji, Y., 1304
 Shpilberg, O., 755
 Shulman, L. N., 2037
 Shuto, T., 1016
 Shyr, Y., 1336
 Sibley, G., 2135
 Sidransky, D., 433
 Siegal, T., 637
 Siegel, L., 557
 Silver, B., 1072
 Silverman, L. B., 1964

Simeone, J., 1082
 Simmons, M. L., 2342
 Simon, L. P., 2824
 Simon, T., 2636
 Simons, J. W., 2606
 Singletary, S. E., 1417, 2054
 Sinicco, A., 563
 Siperstein, A. E., 1139
 Sipponen, P., 996
 Sivak, M. V., Jr., 1788
 Skarsgard, D. P., 1728
 Skingley, P., 2260
 Skrepnik, N., 468
 Slebos, R. J. C., 814
 Sledge, G. W., Jr., 375, 2047
 Sloodweg, P. J., 884
 Small, E. J., 825, 1310
 Smeets, A. W. G. B., 2598
 Smilde, T. J., 2116
 Smith, D. S., 1454
 Smith, R. C., 796
 Smith, T. M., 1703
 Snow, P., 2105
 Sober, A., 1484
 Sobin, L. H., 2887
 Sobrinho-Simões, M., 1766
 Soffer, D., 364
 Soh, D., 1828
 Sohn, Y. W., 2082
 Soini, Y., 1590
 Solin, L. J., 946
 Solin, O., 693
 Somanathan, T., 664
 Sommer, H., 2252
 Sondel, P., 1892
 Sone, Y., 58
 Song, B.-C., 1986
 Song, I. H., 1986
 Soong, S.-J., 1484
 Soong, Y.-K., 2619
 Sorrells, D. S., 2803
 South-East Region Prostate Cancer Group, 1445
 Sperduto, P., 2876
 Spina, M., 563
 Spirtos, N. M., 144
 Spitz, M. R., 1837
 Spotts, B. E., 1663
 Stackiewicz, R., 755
 Stadler, W. M., 1317
 Stafford, S. L., 870
 Stanbridge, E. J., 1108
 Stanford, J. L., 2570
 Stark, B., 205
 Starostik, P., 1359
 Starzynska, T., 1801
 Steg, R. E., 433
 Stegmaier, C., 274

Steinherz, P. G., 1945
 Steinschifter, W., 461
 Stella, P. J., 124
 Stepp, H., 2275
 Sternberg, D. W., 2037
 Stevens, G., 88
 Stewart, A. K., 912
 Sthoeger, D., 205
 Stock, R., 2105
 Stoler, D. L., 1814
 Stolte, M., 996, 1801
 Stone, N., 2105
 Strodel, W. E., 2010
 Stroebel, W., 2534
 Strome, M., 876
 Sturm, V., 2796
 Stürmer, T., 274
 Suenaga, T., 2220
 Sugihara, K., 245, 1304
 Sugimachi, K., 2239
 Sugiyama, K., 58
 Sugiyama, T., 2584
 Suguro, M., 2529
 Suh, D. J., 1986
 Suh, H. S., 1623
 Suhonen-Polvi, H., 693
 Suita, S., 2372
 Suminoe, A., 2372
 Sun, B., 1384
 Sunami, E., 42
 Sung, H.-Y., 2283
 Sung, K.-B., 1986
 Suou, T., 529
 Supportive Care Review Group, 217, 226
 Suter, N. M., 1393
 Sutter, G., 1650
 Suzuki, F., 2471
 Suzuki, M., 2584
 Suzuki, Y., 2471, 2766
 Swanson, G. M., 653
 Swiderski, C., 2010

T

Taberner, J. M., 162
 Tachimori, Y., 1285
 Tada, K., 268
 Tadic, L., 2246
 Tagawa, H., 1530
 Taguchi, K., 2584
 Taicher, S., 984
 Tajima, Y., 1285
 Tajiri, T., 2372
 Takahashi, S., 312
 Takaishi, H., 312
 Takanami, I., 2686
 Takasaki, K., 544
 Takashima, M., 2239

- Takatsu, K., 544
 Takatsuka, Y., 1549
 Takayama, T., 2478
 Takebayashi, Y., 1131
 Takeda, I., 58
 Takeda, M., 2578
 Takeda, N., 2578
 Takenami, K., 544
 Takenoue, T., 2443
 Takeshita, M., 286
 Takeuchi, K., 2686
 Takezako, N., 2529
 Talavera, J. G., 352
 Talmi, Y. P., 984
 Talpaz, M., 570
 Tam, W. Y., 1828
 Tamura, S., 1025
 Tanabe, K. K., 2452
 Tanaka, H., 1016
 Tanaka, M., 2438
 Tanaka, Y., 132
 Tangoku, A., 268
 Tannapfel, A., 1030
 Tanner, B., 1370
 Tao, Q., 761
 Tarabuzzi, R., 2590
 Tashiro, H., 814
 Tavani, A., 786
 Tavaré, C. J., 1477
 Tavassoli, F. A., 2072
 ten Kate, F. J. W., 2429
 Teofili, L., 454
 Terakawa, N., 2584
 Tfayli, A., 2350
 Th. Rutgers, E. J., 1633
 Thakur, V., 1565
 Thaler, H. T., 186
 Theriault, R. L., 1082, 2054
 Thiele, J., 1536
 Thiessard, F., 1696
 Thomas, C. R., Jr., 1517
 Thomas, G., 664
 Thomas, M., 2553
 Thompson, J. A., 1325, 1484
 Thompson, J. D., 1393
 Thompson, J. F., 88, 1484
 Thompson, K. S., 1582
 Thompson, L., 2037
 Thompson, L. D. R., 15, 1149, 2181
 Thornton, D. E., 1807
 Tiebosch, A. T. M. G., 2546
 Tilanus, M. G. J., 884
 Tirelli, U., 563
 Todo, Y., 2578
 Togawa, A., 2529
 Tokuda, K., 577
 Tomaszewski, J. E., 2110
 Tomlinson, G. E., 1687
 Tonato, M., 1438
 Tono, T., 1549
 Torata, N., 2438
 Toren, A., 2845
 Torras, J., 50
 Torta, M., 2590
 Toyoda, H., 58
 Treuer, H., 2796
 Trigo, J. M., 162
 Trip, M. D., 2116
 Trivandrum Oral Cancer Screening Study Group, 664
 Trojanowski, J. Q., 2154
 Tse, V. K. C., 1715
 Ts'o, P. O. P., 2787
 Tsubota, A., 2471
 Tsukamoto, T., 1016
 Tsunematsu, Y., 1970
 Tsuneyoshi, M., 286
 Tsuno, N., 42
 Tsuruo, T., 42
 Tsutsumi, T., 2478
 Tsuyama, S., 245
 Turazzi, S., 169
 Turner, B. C., 1091
 Turner, J. R., 2228
 Turrisi, A. T., III, 1517
 Tyler, D., 1063
 Tytgat, G. N. J., 2429
- U**
 Ubbink, M. C., 2116
 Uchitomi, Y., 2817
 Uckun, F. M., 1945
 Ueda, K., 1955
 Ueda, M., 1524
 Ueno, K., 1574
 Ukkat, J., 1909
 Ulrich-Pur, H., 2505
 Urano, H., 2210
 Urban, J., 749
 Urban, N., 1294
 Utada, Y., 1410
 Utriainen, T., 693
- V**
 Vaccher, E., 563
 Valencak, J., 1979
 Valero, V., 1929, 2054
 Valls, C., 50
 van den Berg, R., 2811
 van den Brandt, P. A., 737
 van der Mey, A. G. L., 2811
 van der Pal, H. P. J., 2116
 Van Hove, W. Z., 1769
 van Lanschot, J. J. B., 2429
 van Oijen, M. G. C. T., 884
 van Sandick, J. W., 2429
 Varenhorst, E., 1445
 Vasini, G., 2731
 Vaskovic, Z., 2246
 Venkatasubbarao, K., 2010
 Vernon, S. W., 2398
 Vernooij-Dassen, M. J. F. J., 900
 Vicini, F. A., 425, 596, 2305, 2553
 Vignal, J., 358, 2512
 Villa, M. R., 75
 Virgili, J., 50
 Virgo, K. S., 777
 Visentin, M. C., 389
 Vlastos, G., 1417
 Vlock, D. R., 2693
 Vogel, C., 2047
 Vogel, I., 2495
 Vogelzang, N. J., 825, 1317
 Voges, J., 2796
 Vohwinkel, G., 344
 Volot, F., 324
 Volpin, L., 169
 Volta, C., 454
- W**
 Wada, S., 2578
 Wagner, H., 1166
 Wai, E., 1852
 Wajchenberg, B. L., 711
 Wakasa, K., 1016
 Waller, A., 984
 Walton, J. A., 1916
 Wanamaker, J. R., 876
 Wang, B. Y., 2774
 Wang, H.-S., 2619
 Wang, J., 381
 Wang, P., 381
 Wang, T.-H., 2619
 Wang, Z.-P., 2787
 Washington, P., 1929
 Watanabe, H., 996, 1285
 Watson, R. W. G., 2092
 Wayand, W., 608
 Weaver, A. L., 1663, 2326
 Weaver, D. L., 1099
 Weber, R., 1842
 Weber, T. K., 1814
 Wei, J. T., 2655
 Weihrauch, M., 1030
 Wein, A., 2110
 Weingandt, H., 2275
 Weir, H. K., 2398
 Weiss, H. L., 2189
 Weiss, M. A., 620
 Weiss, N. S., 2570
 Wemeau, J.-L., 770
 Weng, E. Y., 1643
 West, M. M., 114

Whelan, T. J., 2260
White, W. L., 154
Whiteside, T. L., 2693
Whittington, R., 2110
Widschwendter, M., 1432
Wiencke, J., 2342
Wiggins, J. E., 369
Wilding, G., 1892
Williamson, S. K., 1159
Willis, J., 1788
Wilt, T. J., 1277
Winchester, D. P., 933
Winer, E. P., 825
Wingo, P. A., 2398
Winkenwerder, W., Jr., 2876
Winter, K., 988
Wistuba, I. I., 749
Wittekind, C., 1030
Witzig, T. E., 154
Wolf, W., 2350
Wolff, R. A., 262
Wollner, N., 186
Wolpert, P. A., 433
Wood, B. G., 876
Woodruff, J. M., 66, 2711
Woods, N., 653
Wrensch, M., 2342
Wright, J. R., Jr., 2853
Wszolek, Z. K., 433
Wu, A. H., 1239
Wu, C.-W., 2464
Wu, K., 632
Wunder, J. S., 2721

X

Xiang, W., 2275

Y

Yabuuchi, I., 1025
Yalçin, B., 2033
Yamada, S. D., 2782
Yamaguchi, H., 1285
Yamaji, Y., 1530
Yamamoto, M., 544
Yamamoto, R., 2529, 2578
Yamamoto, T., 1016
Yamaoka, H., 1955
Yamashita, J., 2000
Yamashita, M., 550
Yan, Y., 1122, 1454
Yao, D., 761
Yao, T., 286
Yarkoni, S., 755
Yehuda, D. B., 2357
Ying, Z., 333
Yokoyama, T., 1955
Yoneda, S., 318
Yoo, J., 518
Yoon, H.-K., 1986
Yoshida, H., 1530, 1557
Yoshikawa, A., 295
Yoshimura, K., 1285, 1796
Yoshinaga, K., 1304
Yosimori, K., 318
Yotsuyanagi, H., 2478
Younes, A., 524
Younes, M., 524
Young, J., 1245

Young, J. D., 1122

Yu, C. L. M., 1715

Yu, J., 1801

Yu, Z., 761

Yuh, Y. J., 1623

Z

Zagzag, D., 2606
Zaizov, R., 205
Zambelli, A., 2758
Zaninotto, G., 2520
Zannoni, G. F., 2290
Zatloukal, K., 461
Zeimet, A. G., 1432
Zeng, Y.-X., 255
Zerbini, M. C. N., 711
Zetterquist, H., 2661
Zhang, C.-Q., 255
Zhang, X. Y., 280
Zhengxi, J., 42
Zhong, H., 2606
Zhou, H., 2668
Zhou, S., 1728
Zhou, S. J., 280
Ziaja, E. L., 425
Ziegler, H., 274
Zieske, A. W., 468
Zincke, H., 844, 1679, 2326
Zirbes, T. K., 1536
Zuazu, F., 352
Zubizarreta, P. A., 1939, 2848
Zwinderman, A. H., 2811